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Abstract 
Introduction:  Cardiovascular disease (CVD) remains the number one cause of 
mortality in the world for both men and women, thus improving its diagnosis and 
treatment is a priority.  Rheumatoid Arthritis (RA) is a common auto-immune 
disease associated with high rates of CVD.  Cardiovascular magnetic resonance 
(CMR) offers a multi-parametric, quantitative approach to the assessment of the 
heart and cardiovascular system with a host of techniques allowing assessment of 
anatomy, ventricular function, myocardial composition, myocardial perfusion, 
vascular performance and myocardial metabolism during a single scan.  Its 
quantitative nature and lack of ionising radiation lend themselves ideally to the 
longitudinal study of subclinical CVD. 
Aims:  To assess 1) whether blood longitudinal relaxation (T1) can be used to 
estimate blood haematocrit value to allow calculation of extracellular myocardial 
volume fraction (ECV), 2) whether CMR feature tracking (CMR-FT) is a feasible 
means of assessing aortic stiffness, 3) whether global longitudinal strain (GLS) is 
reduced in patients with prior MI with preserved left ventricular ejection fraction 
versus healthy controls, 4) whether aortic stiffness is present at all time points in the 
disease course of RA and 5) whether subclinical CV abnormalities in newly 
diagnosed RA improve with treatment and if the anti-tumour necrosis α Inhibitor 
Etanercept offers additional benefit over standard treatment. 
Methods:  Patients were recruited between and February 2011 and February 2017.  
All patients underwent a comprehensive, multi-parametric CMR study including cine 
and late Gadolinium enhancement imaging at either 1.5 or 3.0T.  
Results:  1) estimation of blood haematocrit from blood T1 value provides accurate 
estimation of ‘synthetic’ ECV, 2) CMR-FT assessment of aortic stiffness is feasible 
and provides reproducible values for descending and ascending aortic strain 
values, 3) GLS is reduced in prior MI patients versus healthy controls (-17.3 ± 3.7% 
versus -19.3 ± 1.9% respectively, p=0.012).  A GLS cut-off value of 18% correctly 
identifies prior MI with a sensitivity of 60% and specificity of 72.5%, 4) Aortic 
stiffness is evident in at risk RA individuals, newly diagnosed RA as well as 
established RA and 5)  Aortic distensibility and left ventricular mass improve 
significantly in newly diagnosed RA patients following treatment.  Etanercept 
appears to offer additional benefit over standard treatment evidenced by numerical 
improvements in aortic distensibility.  
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1. General Introduction 
1.1. Background  
Since the first reports of in vivo fluoroscopic imaging of the heart in the late 
nineteenth century(1), non-invasive cardiovascular imaging has progressed to 
become an indispensable means of assessing the function of the heart and wider 
cardiovascular (CV) system. 
Cardiovascular disease (CVD) remains the number one cause of mortality in the 
world for both men and women(2), thus improving its diagnosis and treatment is a 
worldwide priority.  As our understanding of the epidemiology of cardiovascular 
disease has evolved over time, there has been increased interest in characterising 
the way in which these diseases develop before they manifest clinically.   
A multitude of factors are driving these efforts towards the characterisation of 
subclinical cardiovascular disease.  Most significantly, the diagnosis of a disease 
before it becomes clinically apparent offers the potential to delay or halt its 
progression before morbidity or mortality ensue, through treatments and/or lifestyle 
changes.  Identifying evidence of cardiovascular disease earlier than has previously 
been demonstrated and before the onset of clinical symptoms potentially offers the 
opportunity to bring forward the initiation of treatment.   
The study of subclinical cardiovascular disease identification of ‘biomarkers’ of a 
disease (measurable indicators of its presence and/or severity) may improve not 
only its diagnosis, but also assess treatment effectiveness, patients most likely to 
benefit from particular treatments as well as assessing their prognosis over time(3).  
Biomarkers may be defined as 1) biological biomarkers – objective, measurable 
indicators of normal, pathological or pharmacological responses to disease or a 
therapeutic agent, or 2) surrogate markers – where a biomarker serves as a 
substitute for a clinically important outcome and therefore it’s level is expected to 
reflect the effect of a disease or therapeutic agent(4).  A scheme of validation has 
been proposed by which new and emerging biomarkers are evaluated and 
developed(5).  Initially the clinical relevance of a biomarker must be proven, for 
instance demonstration of its ability to reflect a plausible and rational physiological 
or pathological change in a biological system.  Additionally, its sensitivity and 
specificity to detect a significant morbidity or mortality outcome within a target 
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population must be demonstrated.  Its reliability must also be demonstrated in terms 
of accuracy, precision and reproducibility (across different assessors, within the 
same assessor and at different time points).  Lastly, a biomarker’s utility in terms of 
practicality and  feasibility (ease and resource intensiveness of performing the test)  
as well as the acceptability of the test to patients needs to be proven.  
The study of subclinical cardiovascular disease, aside from its role in development 
of biomarkers, offers the opportunity to elucidate the pathophysiological 
mechanisms by which it develops into clinical disease, which in turn may provide 
insight into potential therapeutic targets to treat that disease.   
Whereas early non-invasive cardiovascular imaging techniques assessed the heart 
and cardiovascular systems on a gross macroscopic level, cardiovascular magnetic 
resonance imaging (CMR) is able to offer in vivo assessment at tissue and even 
cellular levels.  It provides a comprehensive assessment of cardiac structure and 
function with broad applications in both clinical and research settings. 
Key advantages of CMR include the lack of use of either ionising radiation, 
radioactive isotopes or iodinated contrast agents as are used by alternative 
modalities such as computed tomography (CT), single positron emission computed 
tomography (SPECT) and positron emission tomography (PET)(6).  Images can be 
acquired in any desired plane, without many of the limitations imposed by patient 
habitus or pre-existing lung disease (both key limitations of transthoracic 
echocardiography).  CMR offers a multi-parametric, quantitative approach to the 
assessment of the heart and cardiovascular system with a host of techniques 
allowing assessment of anatomy, ventricular function, myocardial composition, 
myocardial perfusion, vascular performance and myocardial metabolism(7) during a 
single scan.  Measuring quantitative CMR parameters affords accurate comparison 
of these parameters in the same patient over time, comparisons within different 
patient groups, as well as between patients with and without a particular disease.  
Furthermore, a quantitative approach (as opposed to qualitative visual analysis) 
potentially allows for the detection of more subtle abnormalities of cardiac structure 
and function, as well as improved reproducibility.   
CMR is used extensively in the assessment of the effectiveness of treatments in the 
form of surrogate endpoints which are expected to predict clinical benefit or harm.  
Accordingly, these may be used to supplement or even replace ‘hard’ clinical 
outcomes such as mortality and measures of morbidity(8).  Examples where CMR 
provides useful and reliable surrogate endpoints in clinical trials include acute ST 
segment elevation infarct (STEMI).  Here, the quantitative parameters ‘area at risk, 
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‘infarct size’ and salvage index (discussed later in this chapter) can be assessed(9, 
10).  Numerous other potential CMR surrogate endpoints for clinical trials have 
been proposed including dilated cardiomyopathy (DCM)(11) and amyloid heart 
disease(12). 
Key clinical applications of CMR include the assessment of patients with known or 
suspected cardiomyopathy, assessment of the thoracic aorta, characterisation of 
anatomy and cardiac function in congenital heart disease, the evaluation of known 
or suspected coronary artery disease and the assessment of pericardial disease 
and cardiac masses(13).  
Limitations of CMR include its relative expense and contraindications for patients 
with either retained metal objects or older metallic medical prostheses.  The use of 
Gadolonium based contrast agents (GBCA) in patients with severe renal disease 
(eGFR <30ml/min) is contra-indicated as this is associated potentially fatal 
nephrogenic systemic fibrosis(NSF)(14).  Nevertheless, since the introduction of 
routine screening of renal function prior to patients undergoing CMR requiring 
GBCA and restricting its use to patients with acceptable renal function (eGFR 
≥30ml/min), the worldwide incidence of NFS is now extremely low(15). More 
recently however, additional concerns have been raised over the use GBCA.  
Repeated use of linear GBCA compounds have been associated with long-term 
retention of these compounds in areas of the brain including the globus pallidus and 
dentate nucleus(16).  However, the clinical consequence, if any, of this 
phenomenon is not known and further investigation in this area is ongoing.  More 
research is needed before any change is made to clinical guidelines and protocols.  
This chapter aims to discuss current and emerging CMR techniques used to 
evaluate subclinical disease as well as to synthesise and evaluate the key current 
literature surrounding the epidemiology and pathogenesis of both prior myocardial 
infarction (MI) and rheumatoid arthritis (RA), both of which are investigated in 
subsequent results chapters.   
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1.2. Assessing subclinical cardiovascular disease 
with CMR 
1.2.1. Cine imaging by CMR 
Cardiovascular magnetic resonance (CMR) is considered the current reference 
standard for quantitation of left ventricular (LV) and right ventricular (RV) mass, 
volumes and systolic function(7) due to its accuracy and reproducibility.  Aside from 
ventricular volumes, cine imaging provides detailed structural and morphological 
information relating to the cardiovascular system, both of which are key elements of 
clinical CMR reporting.   
CMR methods have undergone considerable evolution and standardisation over the 
past two decades. Today, balanced steady state free precession (bSSFP) is the 
standard for acquisition of cine CMR images as it provides improved endocardial 
border delimitation, shorter scan times and higher signal to noise ratios than the 
formerly used spoiled gradient echo methods(17). The overall better image quality 
of bSSFP acquisition and the ability to more clearly differentiate trabeculation from 
the endocardial border leads to different estimates of LV and RV chamber size, with 
typically larger volumes and lower mass(18).  Parallel imaging may be used to 
improve temporal resolution, in-plane spatial resolution and/or breath hold times of 
bSSFP cine acquisitions and works by undersampling raw image data in the phase 
encoding direction(19).  However, its use is also associated with reduction of signal 
to noise ratio as well as an increase in image artefact. 
Typically cine imaging is acquired using retrospective electrocardiogram (ECG) 
gating, where continuous acquisition of images and ECG signal occurs and is then 
used to reconstruct images by grouping them sequentially according to their relation 
to the R wave on the ECG and thus according to cardiac phase(20).  This ensures 
that all phases of the cardiac cycle are included in cine acquisitions and allows 
corrections to be made to allow for beat to beat variations in heart rate.  
Disadvantages with a retrospective gating technique are reduced image quality 
when the ECG R-R interval is irregular (in the case of arrhythmia) and difficulty in 
acquiring images when the R wave amplitude is low, which is a particular issue on 
3.0 tesla (T) systems.  When image quality is markedly compromised by either of 
these issues, real-time imaging may be used which does not require ECG 
gating(21).  However, this technique is currently severely limited by reduced spatial 
and temporal resolution.   
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1.2.2. Strain imaging by CMR 
CMR may be used in the assessment of myocardial strain.  Myocardial deformation 
imaging or strain imaging is the assessment of myocardial shortening or 
lengthening at either segmental or wider global level during systole or diastole(22).  
Myocardial shortening is assigned a negative value, whereas lengthening is 
expressed as a positive value.  Strain (equation 1) may be assessed in one of three 
cardiac axes; longitudinal, radial or circumferential(23).  
 
Equation 1  Strain equation 
LoLoLStrain /)( 
 
Where L= length in a specific direction after deformation (e.g. radial, 
circumferential, longitudinal planes) and Lo = original length 
 
Traditionally, quantitation of ventricular function has been assessed by expressing 
LV or RV ejection fraction (EF) which is later discussed in the methods chapter.  
Regional ventricular function is typically assessed visually, by describing individual 
LV or RV segments as contracting normally or abnormally.  When regional 
myocardial contraction is visually abnormal this is referred to as a regional wall 
motion abnormality (RWMA).  However, strain imaging offers the potential to detect 
abnormalities in myocardial function at either global or regional level before they 
manifest clinically or are apparent in traditional measures of abnormal myocardial 
function such as ejection fraction, RWMA or ventricular remodelling(24).  Clinical 
applications of strain imaging to date have predominantly been demonstrated using 
speckle tracking echocardiography.  Examples include the demonstration of global 
longitudinal strain (GLS) as a better predictor of mortality than LVEF in heart failure 
with patients with LVEF≥40% (25).  Longitudinal strain is also demonstrably lower in 
patients with early hypertrophic cardiomyopathy (HCM) and, in combination with 
other clinical parameters, may be of use in screening asymptomatic family 
members of affected patients(26).  In patients treated with cardiotoxic 
chemotherapy agents, GLS may be reduced before LVEF, potentially allowing 
earlier adjustments to treatment regimens thereby halting the development of 
clinical heart failure(27).  
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Strain indices are conventionally assessed using CMR by ‘tagging’, which is widely 
considered to be the reference standard non-invasive imaging technique in the 
assessment of myocardial deformation.  The most commonly used CMR tissue 
tagging techniques are referred to as ‘spatial modulation of magnetization’ 
(SPAMM) or ‘complementary spatial modulation of magnetization’ (CSPAMM)(28). 
These require acquisition of specialised images where a grid-like magnetised 
pattern of two orthogonally intersecting lines are superimposed over the imaging 
slice (short or long axis) over the course of the cardiac cycle allowing tracking of the 
pattern in space and time in order to calculate strain values.  The grid-like 
magnetisation effect in SPAMM is achieved with a CMR pulse sequence resulting in 
selective radiofrequency saturation of the ‘tagged’ myocardium through the cardiac 
cycle with a temporal resolution in the region of 15-20ms(29).  The use of CSPAMM 
improves the fading of the grid tags due to longitudinal T1 recovery which occurs 
using SPAMM, at the expense of doubling the required scan time(30).  Although 
CMR tissue tagging produces accurate and reproducible values for both regional 
and global deformation indices,  the technique is limited by the need for a dedicated 
image acquisition scheme and its requirement of time-consuming post-processing 
analysis in order to extract these values; factors which potentially limit its use in 
clinical practice(31).    
CMR feature tracking (CMR-FT) is a newer technique which, rather than requiring a 
specific image acquisition scheme, is able to calculate strain values comparable to 
those obtained with CMR tagging or echocardiographic speckle tracking from SSFP 
(or other) cine acquisitions.  The underlying methodological principles of the 
technique are comparable to speckle tracking echocardiography and use post-
processing computer software to identify features (typically the size of a few pixels) 
appearing within a small window of an image, identifying a comparable feature 
within subsequent image frames and assessing its displacement through space and 
time(32).  This technique works better at endocardial borders than within 
compacted myocardium, probably due to the homogeneity of water content and 
relative lack of distinctive features within myocardium(32).   
Although few studies have compared CMR tissue tagging  directly with CMR FT, 
tissue tagging has been demonstrated to be more reproducible for the 
measurement of segmental strain parameters(33).  However, CMR-FT 
reproducibility is good for global strain indices (both long and short axis) and no 
significant differences are observed between measurements obtained at 1.5 and 
3.0T field strength bSSFP cine acquisitions(34).  
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1.2.3. Assessment of myocardial perfusion by CMR 
Chronic myocardial ischaemia can be assessed using CMR by either visual or 
computerised quantitative assessment of blood flow to the LV myocardium by 
intravenous injection of GBCA and observation of resultant myocardial uptake both 
at rest and during pharmacological vasodilator stress(35).  Hyperaemia is most 
commonly brought about by use of intravenous adenosine infusion.  Adenosine is a 
naturally occurring endogenous cardiovascular signalling molecule which acts on 
A2A and A2B receptors(36).  The half-life of adenosine is short (in the region of 10 
seconds) with very few contra-indications and an excellent safety profile.  
Alternative vasodilator agents which have been used in CMR myocardial perfusion 
assessment include Regadenason and Disopyramide, though these are seldom 
used in the context of CMR perfusion in either clinical practice or research in the 
UK.  Regadenason is used in some centres in the USA (37). 
Images are acquired in 3 short axis slices through the LV to ensure coverage of the 
LV base, mid and apex, a detailed explanation for which is given in the methods 
chapter.  Spoiled gradient T1-weighted echo sequences are the most commonly 
used pulse sequences in CMR perfusion imaging(38) and can be used in 
combination with acceleration techniques such as kt-sense or kt-blast based on 
spatio-temporal undersampling to maximise in-plane spatial resolution of acquired 
data(39), while still enabling acquisition of all 3 short axis slices with each 
heartbeat.  Acquiring images with each heartbeat is crucial to ensure adequate 
temporal resolution and full capture of myocardial uptake of GBCA during its first 
pass through the coronary circulation.  GBCAs shorten T1 time, appearing as areas 
of high signal when present.  Spatial resolution of CMR perfusion analysis without 
the use of acceleration techniques is around 2-3mm, but with acceleration and at 
3.0T field strength (which offers improved contrast and signal to noise ratios) may 
be lower than 2mm(37). 
 
Uptake of contrast agent may be impaired during vasodilator stress either due to 
epicardial coronary artery disease or more distally in the coronary tree in the form of 
microvascular disease.  The presence of flow-limiting, functionally significant 
epicardial coronary artery disease in the clinical setting is conventionally 
determined by qualitative visual assessment.  Abnormally perfused areas of 
myocardium appear as a relatively dark area of myocardium in a coronary 
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distribution.  Conversely, neighbouring normally-perfused myocardium appears 
lighter, with high signal intensity due to higher uptake of contrast agent.   
CMR is commonly used in the assessment of clinical patients with suspected stable 
coronary artery disease.  Meta-analysis has demonstrated that this technique has a 
high sensitivity and specificity for the detection of significant epicardial coronary 
artery disease, estimated at 89 and 76 % respectively for sensitivity and 
sensitivity(40).  Direct comparison of CMR to SPECT suggests that CMR offers a 
higher degree accuracy than SPECT in identifying significant coronary artery 
stenosis on subsequent x-ray coronary angiography(41). 
Besides visual assessment, myocardial perfusion may be assessed in a 
quantitative manner using computer software (normally as a post-processing 
technique applied after the scan has taken place).  Numerous mathematical 
algorithms exist by which to compute myocardial blood flow in ml/min/g, which work 
by equating signal intensity curves through first pass perfusion of blood pool and 
myocardium to GBCA concentration.  Of the algorithms available, Fermi 
deconvolution correlates best with animal model studies of myocardial perfusion 
using fluorescent microspheres as the validation technique(42).  A ‘dual-bolus’ 
technique may improve myocardial perfusion quantification, where a 10% dilute 
GBCA bolus is first infused, followed by a concentrated GBCA bolus.  Perfusion 
quantification relies on a linear relationship between signal intensity and GBCA 
concentration, however, GBCA infusion can induce T-1 saturation and signal 
attenuation in the LV cavity(43).  Use of a dilute GBCA bolus serves to maintain 
linearity of the LV signal intensity, improving the accuracy of blood flow algorithms.  
Quantitative perfusion may circumvent some limitations to visual assessment of 
myocardial perfusion using CMR.  Once such limitation is ‘balanced ischaemia’, 
where globally impaired perfusion is misinterpreted as normal. This may occur due 
to widespread epicardial coronary disease, since visual analysis relies on 
comparing normally perfused areas of myocardium with abnormal areas, yet when 
only abnormal areas are seen, this may be misinterpreted as ‘normal’(10).  
Furthermore, quantitative perfusion may allow more accurate assessment of 
coronary microcirculation dysfunction which typically manifests as a global 
myocardial process(44).  Subclinical impairment of coronary microcirculatory 
function has been demonstrated in a variety of diseases including HCM(45), dilated 
cardiomyopathy(46) and aortic stenosis(47).   
The reference standard technique for quantitative myocardial perfusion is PET(44, 
48), however, good agreement has been shown between PET and quantitative 
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myocardial perfusion by CMR(49) as well as invasively measured fractional flow 
reserve(50). 
1.2.4. CMR Tissue Characterisation Techniques 
A key advantage of CMR lies in its ability to provide ‘tissue characterisation’ of the 
myocardium; detailed information regarding the structure and composition of the 
ventricular myocardium allowing detection and diagnosis of a wide range of 
myocardial diseases(51).   
1.2.4.1. Late Gadolinium Enhancement Imaging 
The most established tissue characterisation technique is late Gadolinium 
enhancement imaging (LGE) whereby a contrast agent is administered to the 
patient allowing visualisation of characteristic patterns of myocardial 
hyperenhancement, which in turn reflect areas of infarction or focal fibrosis(52).  
Contrast diffuses passively into and is retained within infarcted or fibrotic 
myocardium and appears as confluent areas of high signal on LGE due to the T1 
shortening properties of GBCAs (time taken for protons to return to their resting 
alignment after aligning in the longitudinal plane following a ‘saturation’ or 
‘inversion’ pulse) .  The Gadolinium component of GBCAs is bound to a chelate, the 
purpose of which is to reduce toxicity and limit the distribution of GBCAs to the 
extracellular compartment of tissues in the body(53).  In normal tissues with intact 
cellular membranes, this extracellular space is relatively small, however, if acute 
cellular necrosis occurs (e.g. in acute MI) contrast is able to passively diffuse into 
the intracellular space, or if healthy myocardial cells are replaced by substances 
such as collagen as occurs in chronic MI or conditions leading to myocardial 
fibrosis, the extracellular compartment is larger relative to normal which increases 
the distribution of GBCA. Fibrosis itself can be considered as pathological 
remodelling of the extracellular space surrounding cardiac myocytes involving 
deposition of collagen into this space, often leading to stiffness of these 
myocytes(54). 
CMR pulse sequences for acquisition of late Gadolinium enhancement images use  
inversion recovery gradient echo pulse sequences .  Images are acquired 10-15 
minutes following GBCA injection.  Firstly, a variable inversion time scout sequence 
or ‘Look Locker’ sequence is performed allowing selection of the optimal inversion 
time at which the myocardium becomes ‘nulled’ i.e. devoid of signal and appearing 
dark, thus maximising the contrast between normal low signal myocardium and high 
signal areas where GBCA has been retained.  Images are then acquired after 
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applying the appropriate inversion time.  A more recent alternative technique 
termed ‘phase sensitive inversion recovery’ removes the dedicated variable 
inversion time scout sequence needed to determine the optimal inversion time of 
nulled myocardium (and operator dependence on its interpretation) while retaining 
excellent image quality(55). 
In the clinical setting, LGE is useful in the diagnosis and differentiation of numerous 
cardiomyopathies, each of which have characteristic patterns of hyperenhancement 
(56) as well as in the detection of myocardial infarction in both the acute and 
chronic setting. 
Quantification of LGE can be performed using semi-automated post-processing 
software.  These use signal intensity thresholding techniques which incorporate 
mathematical cut-off points to determine normal versus hyperenhancing 
myocardium and have been validated against histology slides from explanted 
hearts and myomectomy tissue demonstrating good agreement between the 
two(57).  Each technique differs in performance and reproducibility, though no 
consensus exists as to the optimal method to use(58).       
The main limitations of LGE are its requirement of GBCA (limiting its use to patients 
with eGFR >30ml/kg/min), its relative inability to demonstrate diffuse as opposed to 
focal fibrotic processes and its inability to differentiate active inflammation from 
chronic, inactive scar(59).  Most of these limitations can be overcome through the 
use of additional assessment of CMR tissue characteristics. 
 
1.2.4.2. T1 Mapping and Extracellular Volume Fraction 
Calculation 
CMR generates images by recording and displaying relative pixel intensity 
according to the relaxation of hydrogen protons in a static magnetic field.  T1 
relaxation time represents the intrinsic spin-lattice magnetic relaxation property of 
tissue or relaxation recovery time of protons in the longitudinal plane after excitation 
with an inversion pulse(60).  Precise T1 values can be calculated of myocardium 
and blood on a pixel-wise basis in the form of ‘T1 maps’ allowing comparison 
between patients and pre-defined normal values (which are vendor and field 
strength dependent).  T1 times vary greatly in different body tissues and to a lesser 
degree within the myocardium itself.  T1 maps represent a composite image 
comprised of individual images at different T1 recovery times(61).  The intensity of 
pixels in the composite image correspond to the T1 time within the corresponding 
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voxel – the brighter the pixel, the longer the T1 recovery time.  Myocardial T1 
mapping provides additional diagnostic information in the form of the magnetic 
relaxation properties of the myocardium on a pixel by pixel basis and may reveal a 
more subtle, diffuse myocardial fibrosis process not evident on LGE imaging, 
without the requirement of contrast agent(62).  A high T1 value may be seen in the 
presence of diffuse myocardial fibrosis, but may also also be elevated in the context 
of myocardial protein deposition and oedema(63).  Conversely, low T1 values are 
typically seen in iron or lipid deposition(63). 
Three main types of pulse sequence can be used to generate T1 maps.  Messroghli 
et al. devised the commonly used Modified Look-Locker Inversion recovery scheme 
(MOLLI) which merges SSFP single shot read-out images at end-diastole from 
multiple Look-Locker experiments at conducted at differing, consecutive inversion 
times to generate maps within a single breath-hold of around 15-20 seconds(64).  
Following on from this work, Piechnik et al. described the shortened MOLLI or 
‘ShMOLLI’ sequence which is a simplified, shortened pulse sequence with fewer 
SSFP readouts and requires a shorter (approximately 10 second) breath-hold to 
acquire(65).  Agreement in values between the two methods is good(65).  SASHA 
is a third, newer pulse sequence and stands for ‘saturation recovery single-shot 
acquisition’.  This uses 10 ECG triggered single shot bSSFP images in a single 
breath hold with a shorter breath hold time than MOLLI.  Performance in phantom 
studies and in vivo is good(66).           
 
T1 mapping techniques in combination with administration of GBCA provide an 
estimate of myocardial extracellular volume fraction (ECV), which expresses the 
relative volume of cardiac tissue not occupied by cells.  ECV can be useful in 
demonstrating more diffuse forms of fibrosis where the post GBCA myocardial 
signal intensity may be isointense and therefore not evident on LGE, which 
highlights localised areas of fibrosis(67).  ECV is estimated from the concentration 
of GBCA within the LV myocardium relative to the blood concentration of GBCA in a 
dynamic steady state(67) and therefore may be derived from an equation 
incorporating myocardial and blood T1 (ms) adjusted for the patient’s haematocrit 
(which influences both of these values).  Full details of myocardial ECV volume 
fraction calculation are provided in the methods chapter.   
 
The relative balance of the cellular and extracellular volumes may be altered by 
varying degrees by various physiological and pathophysiological processes(60, 68–
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70).  ECV measured by CMR has been validated against histologically derived 
myocardial ECV(71).  Furthermore, ECV calculated by CMR shows promise in 
prognostication of mortality and morbidity(68, 72).  Current limitations of the 
technique include ‘partial voluming’ occurring at the myocardial: blood pool 
interface, where a given voxel or voxels comprise T1 values from both myocardium 
and blood pool and therefore represents the average T1 value of the two.  This may 
be obviated by measuring myocardial T1 values from a region of interest in the 
midwall and blood region of interest well away from the myocardium.  However, 
doing so may not detect a true pathological process such as subepicardial or 
subendocardial fibrosis(67).  
 
1.2.4.3. T2 weighted Imaging 
T2 weighted imaging is most commonly performed using short TI triple inversion 
recovery prepared fast spin echo pulse sequences (T2 STIR images).  This 
technique allows acquisition of still images taken in a desired imaging plane with 
bright areas corresponding to areas of high T2 signal with relative suppression of 
signal from both the blood pool and fat.  T2 (or spin-spin relaxation time) itself refers 
to the exponential time constant for the decay in magnetisation occurring in the 
transverse plane following application of a radiofrequency excitation pulse(73).  
This time constant is dependent on interactions of the spin of neighbouring protons, 
hence the term ‘spin-spin relaxation time’(73).  Areas of high water content or 
oedema appear as areas of high signal.  For this reason, this technique is 
particularly useful in and may improve diagnosis of diseases associated with acute 
increases in myocardial oedema such as myocardial infarction, Takotsubo 
cardiomyopathy and myocarditis(74).   
In acute myocardial infarction, the total area of high T2 signal has been shown to 
correspond to the ‘area at risk’ i.e. the volume of myocardium liable to be 
irreversibly infarcted should revascularisation not occur(75).  This can be assessed 
retrospectively (up to one week after the onset of myocardial infarction) so as not to 
delay urgent revascularisation(74).  When the ‘infarct size’ (volume of LV LGE as a 
proportion of the overall LV myocardial volume) is subtracted from the area at risk, 
this corresponds to the amount of myocardium recovered by revascularisation; 
known as the ‘salvage index’.  Both area at risk and infarct size are independent 
predictors of mortality in STEMI patients(9) and provide a means of quantifying the 
severity of an MI.  
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T2 weighted imaging suffers a number of potential limitations.  The first of these 
limitations is regional myocardial T2 signal variation relating to the use of phased 
array coils; the T2 signal may appear less intense the further away it is from the 
surface coil.  Additionally, image quality may be limited by low contrast to noise 
ratio between normal and abnormal myocardium.  Lastly, ‘slow flow artefact’ may 
be present where the blood pool adjacent to less well contracting LV segments 
appears bright due to misregistration between the dark blood preparation and 
image readout imaging phases(76).  These potential limitations need to be 
considered when interpreting CMR T2 images, but may also be in part 
circumvented by T2 mapping. 
T2 maps can be generated by using a pulse sequence which includes a T2 
preparation pulse which is followed by 3 SSFP readouts taken at consecutive 
increasing echo times(77).  These 3 images are then processed to fit the T2 decay 
curve at each pixel within the imaging field in the form of a pixel-wise T2 maps.  
Alternative pulse sequences have also been proposed for the generation of T2 
maps(78).  T2 mapping assessment of patients with proven active myocarditis on 
endomyocardial biopsy has been shown to be more accurate than T1 mapping and 
other CMR parameters in predicting active myocarditis(79).    
 
1.2.4.4. T2* Imaging Using CMR 
T2* imaging using CMR is used primarily in the assessment of patients at risk of 
iron overload and resultant siderotic cardiomyopathy due to disease states such as 
thallasaemia major, sickle cell anaemia and other conditions where patients are 
transfusion dependent.  Intracellular iron has strong paramagnetic properties (as 
occurs in iron overload states) and causes shortening of the T2* decay constant 
due to inhomogeneities in the magnetic field(38).  T2* relaxation time can be 
measured using a gradient echo pulse sequence and correlates very strongly with 
invasively measured in vivo iron concentrations, allowing longitudinal, non-invasive 
assessment of iron loading and adjustments to iron chelation therapy as 
appropriate(80). 
 
1.2.5. CMR Assessment of Vascular Performance 
Arterial stiffness is a recognised surrogate measure of increased CVD risk(81) and 
reflects a generalised process of vascular ageing and atherosclerosis, meaning 
(CMR) quantitation may be a useful biomarker in diseases leading to arterial 
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stiffness.  Increased stiffness within the aortic arterial wall leads to increased aortic 
pulse pressure and increased left ventricular afterload(82).  End-organ damage is 
thought to occur as a result of failure of dampening of the systolic waveform by the 
aortic wall, exposing the low vascular resistance cerebral, cardiac and renal 
vascular systems to increased haemodynamic load(82).  This has been proposed to 
lead to arterial remodelling, thickening of the arterial wall and eventual 
atherosclerotic plaque formation(83).  
A number of techniques exist by which to quantitatively assess arterial stiffness.  
Aortic stiffness is most commonly measured by aortic pulse wave velocity and 
augmentation index(84).  These have conventionally been assessed by 
‘applanation tonometry’ using use a transcutaneous device such as the 
Sphygmocor device(85) to record the pulse pressure waveform in order to derive 
these values.   
Pulse wave velocity is the ‘propagation speed of the pressure or the velocity wave 
along the artery…calculated as the distance separating two locations and the transit 
time needed for the wave to cover this distance’(86).  CMR may be used to 
calculate pulse wave velocity in a simple fashion, requiring phase-contrast 
acquisitions planned perpendicular to the proximal ascending and descending 
aorta, as well as the distance between these two sites of aortic waveform 
measurement(87).  
Augmentation index is measured either at the radial or carotid artery and is defined 
as the change in pressure between the first and second systolic peaks of the 
arterial waveform as a percentage of the pulse pressure(88).  Using meta-analysis, 
augmentation index has been demonstrated to predict cardiovascular mortality 
independently of peripheral blood pressure(89).  
An alternative means of assessing aortic stiffness is aortic distensibility (AD) which 
can be measured by CMR and has been validated against the reference standard 
technique(90).  Using CMR to assess aortic stiffness as a research application is 
particularly attractive, as its multi-parametric approach allows for simultaneous 
assessment of other cardiovascular abnormalities.  Aortic distensibility measures 
the elastic property of the large arteries and is determined by the difference in 
systolic and diastolic blood pressure and changes in cross-sectional aortic area 
between diastole and systole(91).  Although AD naturally decreases with age, it has 
been shown to be significantly reduced in patients with renal disease(92) and 
significant coronary artery disease(93) versus age-matched controls.  Furthermore, 
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aortic distensibility has been shown to be an independent predictor of mortality in 
hypertensive patients(94).           
1.3. Epidemiology and Pathogenesis of Myocardial 
Infarction 
1.3.1. Epidemiology of Myocardial Infarction 
Myocardial infarction is a leading cause of mortality worldwide, defined as 
‘myocardial death due to prolonged ischaemia’(95).  In the UK alone, over 915,000 
people are estimated to have previously had an MI and coronary artery disease 
was responsible for 73,500 deaths in 2012, representing 16% of all male and 12% 
of all female deaths(96).  NHS spending on treating coronary artery disease is 
estimated at £6.8 billion pounds each year, representing a significant proportion of 
the total spending budget(96).   
1.3.2. Pathogenesis of Myocardial Infarction 
The onset of MI is classically heralded by typical symptoms of chest pain, 
diaphoresis and dyspnoea.  Nevertheless, a proportion of patients may have either 
vague symptoms or absence of any symptoms; frequently in these instances MI is 
unrecognised at the time of its occurrence(97).  Myocardial cell death can occur in 
as little as 20 minutes after ischaemia begins, with complete necrosis occurring 
after between 2 and 4 hours(95).  The pattern of myocardial damage caused by MI 
has been termed the ‘wavefront phenomenon’ where distal tissues within the 
coronary vascular bed are affected first (endocardial), followed by more proximal 
tissues (epicardial)(98).  Interruption to myocardial blood supply resulting in 
myocardial infarction can be caused by one of a number of mechanisms.  These 
are summarised in the following table: 
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Table 1-1  Classification of Myocardial Infarction  
(adapted from Thygeson et al. Third Universal Definition of Myocardial Infarction. 
JACC 2012.  60 (16); 1581-98) 
 
MI Classification Description 
Type 1 Spontaneous plaque rupture or dissection within an 
epicardial coronary artery. 
Type 2 MI secondary to ‘ischaemic imbalance’ – myocardial 
oxygen supply is temporarily outstripped by demand as a 
result of brady- or tachycardia, hypotension, respiratory 
failure etc.  
Type 3  Myocardial infarction resulting in death  
Types 4a/4b/5 Myocardial infarction resulting from PCI (4a) or 
thrombosis of existing coronary stent (4b) or coronary 
artery bypass grafting (5) 
  
 
Following myocardial infarction, the heart undergoes a complex process of post-
infarction remodelling.  Necrotic myocardium becomes replaced by fibrotic scar, 
while non-infarcted myocardium serves to maintain adequate cardiac output in 
order to compensate for the reduced contribution to this by infarcted regions of the 
heart(99).  Autopsy studies suggest this process may take around 6 weeks(100).  
CMR has shown a 40% reduction in infarcted LV mass measured by LGE at 4 
months compared with at the time of infarction, with little interval change at 12 
months, suggesting the majority of the remodelling process is largely complete 
within 4 months(101).  Over the days and weeks following MI, depending on the 
size of infarction, the LV may dilate; with larger infarcts and those involving the 
anterior as opposed to inferior or circumflex coronary territories associated with 
greater LV dilatation(102).  LV chamber enlargement is thought to occur due to a 
combination of thinning with concurrent expansion along the circumferential length 
of infarcted myocardium, coupled with circumferential lengthening of the remote 
(unaffected) myocardium(103). 
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1.4. CMR assessment in myocardial infarction 
CMR offers a comprehensive assessment of cardiovascular function following 
myocardial infarction, providing detailed prognostication and the potential to guide 
clinical decision-making.  Firstly, assessment of left ventricular function aids both in 
long-term prognostication(104) (primarily through assessment of LVEF) and in 
making treatment decisions in terms of heart failure management(105) and complex 
device therapy(106).  CMR may be used to investigate patients with chest pain, 
raised troponin and normal/near normal findings on invasive coronary angiography 
(termed ‘Myocardial Infarction with Non-Obstructed Coronary Arteries’ or 
MINOCA(107)), arriving at a conclusive diagnosis in a high proportion of 
patients(108). Ordinarily, left ventricular function following myocardial infarction is 
assessed using transthoracic echocardiography, though CMR may be used where 
this is not feasible(105).  Additionally CMR may be used to assess the functional 
significance of residual coronary lesions following myocardial infarction(105). 
CMR is frequently used in the assessment of myocardial viability in patients with 
chronic ischaemic heart disease.  In a landmark paper, Kim et al.(109) 
demonstrated that an increasing transmural degree of myocardial 
hyperenhancement on LGE corresponded inversely with the likelihood of successful 
functional recovery of myocardial contractility following revascularisation with 
coronary artery bypass grafting or percutaneous coronary intervention (PCI).  
Where no hyperenhancement by LGE was noted in a myocardial segment with 
reduced contractility, contractility improved in 78% of patients, whereas >75% 
transmural hyperenhancement corresponded with functional improvement in under 
2% of patients.  Meta-analysis of studies using similar LGE-guided 
revascularisation with PCI demonstrated a weighted sensitivity of 87% and 
specificity of 68% to detect hibernating myocardium using a cut-off of 50% 
transmurality of LGE(110).  However, any potential mortality benefit resulting from 
such LGE-guided revascularisation remains to proven in a large scale prospective 
study.   
Parameters measurable by CMR other than LVEF alone may improve 
prognostication of patients post myocardial infarction.  Parameters which are useful 
in this setting include the presence of microvascular obstruction (MVO), 
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intramyocardial haemorrhage (IMH) and LGE.  MVO may occur soon after the 
onset of MI and refers to a cascade of deleterious events within small vessels which 
prevent perfusion of the myocardium(111).  This process is linked to factors 
including small vessel vasoconstriction, myocardial oedema, swelling of capillary 
endothelial cells and micro-embolisation of debris leading to plugging of small 
vessels(112).  Intramyocardial haemorrhage represents an extreme form of MVO 
resulting in damage to small vessel endothelium and extra-vasation of red blood 
cells into the core of the infarction(113).  MVO appears as an island of hypo-
enhancement within the bright, hyper-enhanced areas of infarction on LGE imaging 
whereas IMH appears as a hypo-enhancement on T2 STIR or T2* imaging within 
surrounding areas of infarction and oedema(114).  Both MVO and IMH are now 
established independent predictors of CV mortality in patients with MI(112).  In the 
context of prior, unrecognised infarction, the proportion of infarcted myocardium on 
LGE correlates strongly with mortality and adverse CV events.  Even a small 
amount of infarcted myocardium (mean 1.4% infarcted myocardium on LGE) 
corresponded to a 7-fold increase in mortality in a cohort of patients with 
unrecognised prior MI(115).  
1.5. Epidemiology and Pathogenesis of 
Cardiovascular Disease in Rheumatoid Arthritis 
1.5.1. Epidemiology of CVD in RA 
Rheumatoid arthritis is a chronic autoimmune inflammatory arthritis which affects 
not just the joints, but multiple organ systems including the heart and cardiovascular 
system.     
Rheumatoid arthritis affects up to 1% of the general population and is associated 
with increased mortality.  This is predominantly, though not exclusively due to an 
accelerated process of atherosclerosis affecting the coronary and cerebral arterial 
systems(116).  Overall, there is a 50% increase in cardiovascular mortality amongst 
patients with RA(117), similar in magnitude to that associated with diabetes(118).  
The increased relative risk of CVD compared with the general population appears 
to be most profound in younger patients(119).   
The process of accelerated atherosclerosis seen in RA typically manifests as 
coronary artery disease (CAD)(120) which in turn predisposes to myocardial 
infarction (MI), heart failure due to reduced ejection fraction and sudden cardiac 
death due to heart arrhythmia.  Patients may already have developed 
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cardiovascular disease by the time RA has been diagnosed; patients with RA are 
three times more likely to have had either an acute MI or unrecognised MI in the 
two years preceding formal diagnosis than age and sex matched individuals without 
RA.  This risk continues after diagnosis as patients with RA have a twofold higher 
risk of acute MI compared with those without the disease(121).  Acute MI in patients 
with RA is associated with a more severe presentation compared with the general 
population and worse short term outcomes(122). 
For this reason, both the European League Against Rheumatism(123) and 
European Society of Cardiology(124) recognise RA as a CVD risk factor and 
advocate risk stratification with a view to primary CVD prevention medication in 
patients deemed at high CVD risk.  Non-invasive imaging including measures of 
arterial stiffness may be used to predict CVD risk, particularly when patients are on 
the border of decisional thresholds(125).  
Aside from CVD relating to accelerated atherosclerosis, RA is associated with a 
constellation of other disease processes affecting the heart including myocarditis, 
pericarditis, aortitis, left ventricular dysfunction and valvular disease( figure 1-1).   
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Figure 1-1  Pathogenic mechanisms of CVD in RA 
 
Coronal SSFP still frame image depicting the pathogenic mechanisms causing 
cardiovascular disease in Rheumatoid Arthritis 
 
 
 
Myocarditis is inflammation of the myocardium and is a common finding of RA at 
autopsy(126, 127).  Although rarely clinically significant it can infrequently cause 
significant morbidity or even death(128).   
Pericarditis, a pathological process involving inflammation of the pericardial layers 
surrounding the heart, is a frequent finding in RA(129) present in a high proportion 
of patients at autopsy(126).  Often this is clinically silent, but may rarely cause 
significant symptoms due either to pericardial effusion or pericardial constriction 
where the pericardial layer becomes thickened and encases the heart leading to 
ventricular interdependence, reduced cardiac output and eventually to 
breathlessness and overt heart failure. 
Clinically apparent large vessel vasculitis including aortitis in RA is uncommon, 
occurring in 1-3% of patients(130).  Nevertheless low-grade, clinically silent aortic 
inflammation may be a common feature of RA and contribute to both 
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atherosclerosis and endothelial dysfunction seen in this disease(131).  Histological 
analysis of arterial biopsy specimens from patients with inflammatory rheumatic 
disease undergoing coronary bypass surgery has revealed high rates of 
inflammatory cell infiltrates(132).  Furthermore, 18-fluorodeoxyglucose PET imaging 
has shown increased uptake of radiotracer in the aortic wall of RA patients versus 
controls, which remained significant after adjustment for CVD risk factors(133).  In 
the same study, radiotracer uptake in the aortic wall correlated strongly with 
synovial activity in RA patients(133). 
Left ventricular dysfunction is a common finding in RA, occurring in both diastolic 
(impaired ventricular relaxation) and systolic forms (impaired ventricular 
contraction).  RA patients frequently develop heart failure but often without 
displaying the common symptoms and clinical signs as patients in the general 
population and mortality is worse in RA patients as compared with non-RA 
patients(134). 
Patients with RA frequently have higher rates of valvular heart disease than the 
general population, predominantly in the form of mitral regurgitation (MR).  This is a 
frequent finding on echocardiographic assessment of RA patients as well as 
autopsy though rarely clinically significant(135).    
 
1.5.2. Pathogenesis of CVD in RA 
RA is proposed to exhibit cardiovascular abnormalities through a variety of 
biological mechanisms relating to both the disease itself and, in some instances, 
treatments used to control patients’ symptoms. 
1.5.2.1. Abnormalities in lipid profile in RA 
Abnormalities in lipid profile have been demonstrated in RA patients.  During 
periods of high levels of inflammation, RA is associated with reduced total and low 
density lipoprotein levels (LDL), combined with increased high density lipoprotein 
(HDL) levels(136).  A ‘lipid paradox’ was described by the authors of a large RA 
cohort study where, paradoxically, lower total cholesterol (<4mmol/L) was 
associated with a 3.3-fold increase in CV events(137).  Furthermore, insulin 
resistance in established RA is reported(138).   Whether any changes in lipid profile 
beyond total cholesterol values are associated with increased CVD risk in RA is an 
area of active investigation.  
- 22 - 
 
1.5.2.2. Deleterious CV effects due to RA therapies 
Treatment for RA has been revolutionised in the past 30 years; where debilitating 
disease with profound morbidity was once the norm, with early diagnosis and the 
introduction of newer therapies this has instead become the exception.  
Glucocorticoids such as Prednisolone have been prescribed for many years to 
combat the acute symptoms of pain and inflammation associated with RA.  
However, use of this class of drug demonstrates a clear link with deleterious effects 
on the CV system.  Glucocorticoid use is associated with insulin resistance, obesity 
and diabetes(139).  Within the RA population, patients with active disease 
randomised to 7.5mg Prednisolone daily as opposed to placebo had significantly 
increased systemic blood pressure as well as raised levels of total cholesterol(140).  
The use of long-term high dose Prednisolone (mean dose >7.5mg daily) has been 
associated with significantly increased CV mortality in patients with RA in a large 
observational study(140). 
1.5.2.3. Endothelial dysfunction and atherogenesis in RA 
In spite of findings of lipid abnormalities and insulin resistance in RA, these alone 
are insufficient to explain the increased incidence of CVD in RA.  Vascular 
dysfunction mediated raised levels of circulating pro-inflammatory proteins has 
been proposed as being a major contributing factor to increased CVD risk in RA.  
Outside of the heart, the cardiovascular system is divided into its macrovascular 
(aorta and large arteries) and microvascular component (smaller arteries, arterioles 
and capillaries).  This is lined by the endothelium which regulates circulatory 
function via the release of vasoactive molecules such as nitric oxide (NO), 
prostacyclin and endothelin-1(141).  It has been suggested that in RA, the release 
of pro-inflammatory molecules in patients with RA such tumour necrosis factor 
alpha (TNFα) and Interleukins 1 and 6 leads to a step-wise process of micro and 
macrovascular endothelial dysfunction, followed by atherosclerotic plaque 
formation(142).  The initial phase of endothelial dysfunction is initiated by reduced 
bioavailability of NO via downregulation of the enzyme responsible for its 
production(143, 144).  This results in reduced endothelial dependent dilatation of 
the macro and microcirculation(145) thought to occur due to relaxation of the 
passive tone provided by the smooth muscle layers within the arterial wall(146).   
Chronic endothelial dysfunction is followed later by a second stage characterised by 
accelerated atherosclerosis and eventual atherosclerotic plaque formation(147).  
The complex process of atherosclerotic plaque development begins with an initial 
phase of intimal thickening, where there is proliferation of smooth muscle cells 
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within the tunica intima and overall thickening of this layer(148).  This is followed by 
the accumulation of foam cell macrophages within the intimal layer and ‘xanthoma 
formation’ (figure 1-2)(149).  Plaque formation eventually occurs due to deposition 
of lipid rich material and cell debris within the tunica intima by foam cells.  
Additionally, with plaque formation, the loose connective tissue of the tunica intima 
becomes replaced by collagen-rich, non-compliant fibrous tissue(148). 
 
Figure 1-2 Atherosclerotic plaque formation 
 
Panel A shows healthy artery in cross section.  Panel B shows arterial 
atherosclerotic plaque formation in cross section. 
 
 
1.5.3. Effects of disease-modifying anti-rheumatic drugs on 
the cardiovascular system 
1.5.3.1. Conventional and biologic DMARD 
Methotrexate (MTX) is a conventional synthetic disease-modifying anti-rheumatic 
drug (csDMARD) used as first line therapy in the treatment of RA(150) which exerts 
its effects through inhibition of folate metabolism and inhibition of cellular 
proliferation.  A 2012 meta-analysis assessing the effectiveness of Methotrexate 
across 10 separate clinical trials demonstrated a 21% reduction in total 
cardiovascular risk.  The reason for this apparent benefit and the mechanisms by 
which it reduces CVD remains unclear, however(136). 
Pivotal work in the 1980’s led to the appreciation of the central role of pro-
inflammatory cytokines in RA pathogenesis, in particular, interleukin-1 (IL-1) and 
tumour necrosis factor (TNF)(151). TNF and IL-1 are key innate immune system 
cytokines (152).  Levels of TNF have been shown to be raised in areas of active  
inflammation in RA in patients with RA(153).  The tripartite demonstration of raised 
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TNF levels in synovial tissue(154), in vitro synovial cell culture experiments(155) 
and the in vivo effects of therapeutic antibodies against TNF in pre-clinical 
models(156) confirmed TNF’s importance(157, 158). Similarly, blockade of IL-1 
suggested its therapeutic potential.  
This led to the development of targeted biological therapies in the form of anakinra 
(IL-1 receptor antagonist) and several TNF-inhibitors (TNFi). Whilst anakinra is no 
longer used in treatment of RA due to poor clinical effectiveness,  TNFis are used 
extensively, when csDMARDs (including MTX) have failed to achieve low disease 
activity or remission. 
1.5.3.2. Biologic DMARD and effect on CVD in patients with 
RA Endothelial dysfunction  
Use of TNFi in RA appears to reduce cardiovascular mortality(159), which is 
thought to be related the reduction in inflammation rather than by modifying 
cardiovascular risk factors(136).  Treatment with TNFi therapy has been shown to 
reduce aortic stiffness compared with untreated patients(160), suggesting that 
improvements in endothelial function and/or disruption of atherogenesis may 
underpin the apparent improvements in CV mortality seen with TNFi medications in 
RA. 
Over recent years, a great deal of research has been conducted in assessing the 
role of interleukin-1 (IL-1) in cardiovascular disease as a whole.  IL-1 is a pro-
inflammatory cytokine and is raised in the presence of CVD risk factors such as 
hypertension, smoking and diabetes, as well as in RA(161).  Raised levels are 
associated with endothelial dysfunction and resultant atherogenesis(161) as well as 
adverse LV remodelling in the context of heart failure(162).  Direct inhibition of the 
IL-1 receptor inhibitor with the biological IL-1 inhibitor Anakinra has been shown to 
result in multiple short and longer term effects on the cardiovascular system.  In a 
small scale study of 23 RA patients randomised to receive a 30-day course of 
Anakinra, flow mediated dilatation of the brachial artery (a marker of endothelial 
dysfunction), coronary flow reserve, vascular performance and longitudinal LV S 
prime by echocardiography were all significantly improved in comparison to RA 
patients used as controls who did not receive Anakinra(163).  The same group 
randomised 80 RA patients with and without coronary artery disease (CAD) to 
receive Anakinra or placebo.  IL-1 inhibition with Anakinra significantly improve 
flow-mediated dilatation of the brachial artery, coronary flow reserve, multiple 
measures of vascular performance and LV global longitudinal function 3 hours after 
its administration(164).  Effects were more marked in patients with RA patients with 
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coronary artery disease than those without.  These two studies highlight the role IL-
1 plays in contributing to some of the CV abnormalities seen in RA, as well as 
suggesting that a subset of patients with CAD may potentially derive more benefit 
from treatment with Anakinra.  However, a trial assessing the efficacy of Anakinra 
against TNFi therapy failed to demonstrate any benefit over TNFi therapy in terms 
of RA disease activity, though CV outcomes and surrogate measures were not 
assessed (165).   
These data provide insights into the pathogenesis and treatment effectiveness of 
CVD in RA. Assessing the efficacy of RA treatments in ameliorating the CVD 
effects of the disease in clinical trials of RA is inherently challenging; the expected 
clinical CVD event rate is low and disentangling whether RA or an alternative 
confounding disease process is the cause of a clinical event or CV abnormality is 
difficult(166).  This highlights the potential role of CMR and other non-invasive 
imaging modalities in further clarifying CV outcomes in RA, as well as advancing 
our understanding. In particular, the quantitative, multi-parametric approach of CMR 
offers the capability to shed further light onto the mechanisms by which RA effects 
the CV system as a whole and possibly identify potential CVD biomarkers in RA to 
risk stratify and inform on treatment effectiveness. 
 
1.6. CMR Assessment of RA 
A limited number of studies using CMR have sought to characterise the effects of 
RA on the heart and cardiovascular system.  The small number of studies published 
to date are limited by inclusion of patients with long-established disease treated 
with a wide range of treatment regimens as well as small sample sizes. 
Giles et al(167) compared basic structural CMR findings in 75 patients with 
established RA (mean disease duration 7 years) with no known cardiovascular 
disease with 225 age and gender matched healthy controls.  RA patients with 
known risk factors for cardiovascular disease (hypertension, hypercholesterolaemia 
etc.) were not excluded, however, prevalence of these risk factors was comparable 
to those in healthy controls.  They reported that indexed LV mass was strikingly 
lower in RA versus controls (mean 63g/m2 versus 76g/m2 p=<0.001).  
Furthermore, reduced LV mass was significantly and independently associated with 
use of biological DMARD use and anti-cyclic citrullinated peptide (ACPA) titre (an 
autoantibody which serves as a marker of RA disease severity(168)).  
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In the most comprehensive CMR study of RA patients to date, Ntusi et al. (169) 
assessed 39 RA patients and the same number of age and gender matched healthy 
controls using a multi-parametric CMR protocol at 1.5T.  This protocol included T1 
mapping, T2 weighted imaging, extra cellular volume (ECV) imaging and late 
Gadolinium enhancement imaging in addition to a comprehensive LV function 
analysis including assessment of circumferential systolic strain values by tagging.  
RA patients had a mean disease duration of 7 years, no known history of 
cardiovascular disease and comparable rates of cardiovascular risk factors as 
healthy controls.  Native myocardial T1 values were increased in RA patients 
versus controls (973 versus 961ms respectively, p = 0.03).  Global T2 signal 
intensity values were no different in RA patients versus controls, though in some 
patients, areas of focal oedema were noted.  ECV values were higher in RA 
patients than controls (30.3 versus 27.9%, p = <0.001).  46% of RA patients had 
evidence of non-ischaemic, focal LGE which tended to be patchy and mid-wall and 
5% had evidence of previously undiagnosed prior myocardial infarction. 
Circumferential strain and strain rate were significantly lower in RA versus healthy 
controls.  Both native T1 values and ECV correlated moderately with disease 
activity as well as with circumferential strain and strain rate.  The authors concluded 
that CMR is able to detect both diffuse and focal myocardial fibrosis and myocardial 
inflammation in patients with RA, postulating that myocardial fibrosis in RA is likely 
to be the final common pathway of contributing factors including microvascular 
disease, epicardial coronary disease and chronic myocarditis.      
Using CMR at 1.5T, Kobyashi et al demonstrated coronary microvascular 
dysfunction in a pilot study of 18 patients with established RA and no other known 
cardiovascular disease(170).  The cardiac MR protocol included myocardial 
perfusion at rest and at stress using intravenous adenosine, as well as late 
Gadolinium enhancement imaging. Presence or absence of perfusion defects was 
judged visually and classified as being segmental (following the distribution of a 
coronary artery or arteries) or non-segmental.  Two patients (11%) were 
demonstrated to have perfusion abnormalities at stress but not at rest; one of these 
being a circumferential subendocardial defect and the other a non-segmental 
subendocardial defect.  Although a small-scale study limited in robustness by the 
lack of inclusion of a control group or test to exclude the presence or absence of 
flow-limiting coronary artery disease, this hints at underlying process of coronary 
microvascular dysfunction in RA given the distribution of perfusion defects 
demonstrated.   
 
- 27 - 
 
1.6.1. Other key non-invasive imaging studies in RA 
Non-invasive imaging techniques other than CMR have been used to investigate 
the effects of RA on the heart and cardiovascular system.   
Myasoedova et al assessed basic LV and RV structure and function in a large 
transthoracic echocardiography study of 200 established RA patients (mean 
disease duration 10 years) and 600 age and gender matched healthy controls(171).  
Similar to the Giles et al. CMR study, the authors reported lower indexed LV mass 
in RA versus healthy controls (84.6 versus 91.7 g/m2 respectively, p = <0.001). 
There are some conflicting reports of higher LV mass in patients with RA in 
echocardiography studies(172, 173), however, this probably reflects the relatively 
low accuracy of echocardiography-derived LV mass measurement in general (not 
specific to these studies) and the small sample sizes of the currently available 
reports.  
One key echocardiography study using involving asymptomatic RA patients (mean 
disease duration 14 years) RA with no history of CVD and age and gender-matched 
controls reported significantly reduced S’ values (a measure of LV longitudinal 
systolic function) and higher E/E’ values (indicating increased left ventricular filling 
pressure) in RA patients versus controls(174).  This was a large scale, prospective 
study of 198 patients with established RA and may indicate asymptomatic 
progression of diastolic LV impairment in RA patients with simultaneous evolution of 
subclinical LV systolic impairment. 
Recio-Mayoral et al. assessed myocardial blood flow using PET in 12 patients  with 
established RA versus 25 age and gender-matched healthy controls(175).  All RA 
patients underwent CTCA to exclude significant coronary artery disease.  This 
showed abnormalities of hyperaemic myocardial blood flow and coronary flow 
reserve (difference between resting and maximal coronary blood flow) in patients 
with RA in the absence of flow-limiting coronary artery disease and cardiovascular 
risk factors.  This again indicates a likely subclinical impairment of coronary 
microvascular function occurring with established RA. 
 
1.7. Future Directions 
The study of subclinical cardiovascular disease using CMR looks set to advance 
rapidly over the coming years in a number of key areas including faster, more 
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patient-friendly imaging with diminished reliance on breath-held acquisitions, 
molecular imaging and flow analysis(176).  
Molecular imaging (such as PET) allows visualisation of biological targets within the 
heart by revealing the location and degree of uptake of specific molecules.  Hybrid 
techniques including PET-CT and PET-MRI which theoretically combine the 
advantages of both approaches are being assessed(177).  Future approaches 
using molecular imaging may allow the ability to track uptake of radiolabelled 
therapeutic agents, providing information on disease activity and treatment 
efficacy(178).  Advancements are also being made in the development of 
‘hyperpolarised’ molecules for use in CMR which can be used to assess their 
intracellular metabolism rather than uptake of the molecules within the tissues of 
the CV system(179).  This could aid diagnosis of specific diseases and improve 
quantitation of myocardial perfusion.  
Lastly, flow analysis using CMR is likely to undergo significant improvements using 
time-resolved phase contrast (4-D flow) MRI.  This could in future offer the potential 
to fully assess haemodynamics in any desired location within the cardiovascular 
system as an adjunct to existing multi-parametric assessment provided by 
CMR(180). 
 
1.8. Summary 
The study of subclinical cardiovascular disease offers the opportunity to accurately 
detect and monitor this disease over time and in response to treatment.  This is 
crucial to patients and offers the potential to initiate treatment before the 
development of clinical disease as well as the chance to assess the effectiveness of 
treatments at an individual or population level.  
CMR offers a non-invasive CV imaging technique which ideally lends itself to the 
assessment of subclinical disease and provides an ever expanding range of 
reproducible, multi-parametric quantitative techniques in a single scan which can be 
performed safely and in a longitudinal fashion in the same patient if required.   
Key areas of research in the context of MI include improving the identification of 
patients with unrecognised MI, potentially allowing earlier commencement of 
secondary preventative therapies.  Key areas for research in RA include 
characterisation of the timing in the disease course of cardiovascular involvement, 
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improved risk stratification and assessing the effect of disease modifying anti-
rheumatic drug (DMARD) therapy on the cardiovascular system. 
1.9. Thesis hypothesis and aims 
1.9.1. Hypothesis 
1) The utility of CMR can be expanded to broaden its current repertoire of non-
invasive imaging biomarkers to assess subclinical cardiovascular disease 
according to published frameworks for development of novel CV 
biomarkers.  
2) Existing non-invasive imaging biomarkers as well as those developed within 
this thesis can be applied to the detection of and effectiveness of treatment 
in both myocardial infarction and rheumatoid arthritis  
1.9.2. Aims 
1) To assess the utility of blood bool T1 in the estimation of laboratory 
haematocrit and the subsequent estimation of extracellular myocardial 
volume fraction (ECV) a biomarker of subclinical myocardial disease 
(chapter 3). 
2) To assess the reproducibility and feasibility of measuring aortic radial and 
circumferential strain using CMR feature tracking post-processing software 
applied to SSFP cine imaging (chapter 4). 
3) To investigate the ability of CMR assessment of longitudinal strain 
parameters assessed using post-processing CMR feature tracking software 
to correctly identify the presence of prior myocardial infarction (chapter 5). 
4) To 1) use CMR measures of aortic stiffness (including those developed in 
chapter 4) to identify the presence of subclinical cardiovascular involvement 
in patients at risk and with newly diagnosed, treatment naïve RA and 2) to 
assess whether these CMR measures of aortic stiffness are able to identify 
patients likely to be at very high CV risk with carotid atherosclerotic plaque 
(chapter 6). 
5) To use a multiparametric CMR study to assess the relative ability of 2 
differing RA treatment strategies to reverse aortic stiffness and other 
markers of CVD in newly diagnosed, treatment naïve RA (chapter 7).  
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2. Methods 
Methodology common to all results chapters is detailed in this section.  The 
methods described herein are established, validated CMR techniques described in 
the literature.  The development of two novel techniques using CMR, synthetic ECV 
and aortic strain by CMR-FT are described in subsequent chapters- chapters 3 and 
4 respectively.  Methodology for these techniques as well as any other techniques 
specific to individual results chapters is included within the methods section of 
those relevant chapters. 
2.1. Scanner Hardware 
All scans at 3.0T were conducted using the same 3.0T system (Achieva, Philips, 
Best, The Netherlands) using the same 32-channel coil, vectorcardiographic 
triggering and multi-transmit technology (Philips, Best, The Netherlands). 
All scans at 1.5T were conducted using the same 1.5T system (Ingenia, Philips, 
Best, The Netherlands) using the same 32-channel coil, vectorcardiographic 
triggering and multi-transmit technology (Philips, Best, The Netherlands). 
2.2. CMR Protocols 
The components of the basic CMR protocol performed in all patients in subsequent 
results chapters (chapters 3-7 inclusive) are outlined in the sections below.  Any 
additions to this basic protocol specific to individual results chapters are detailed 
within each relevant chapter. 
Each CMR study was typically performed within 60 minutes in the order illustrated 
in figure 2-1. 
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Figure 2-1  Study protocol 
 
2.3. Cine Imaging 
Multi-slice, multi-phase SSFP sequence cine imaging was obtained breath-held at 
end expiration and included 2 chamber (2Ch) (single slice), 4 chamber (4Ch) 
(single slice) and left ventricular short axis stack (10-14 slices to ensure full LV 
coverage) acquisitions.  Scan parameters for these cine acquisitions were as 
follows: echo time (TE) 1.48ms, repetition time (TR) 3.0ms, flip angle 45°, field of 
view 320 to 420mm depending of patient size, slice thickness 10mm, 30 phases.  
A further SSFP axial cine acquisition was obtained of the thoracic aorta at the level 
of the PA bifurcation to enable calculation of aortic stiffness parameters.  Survey 
images and a sagittal oblique view of the thoracic aorta were used to plan the axial 
cine acquisition perpendicular to the descending and ascending aorta as described 
by Lee et al(181).  Scan parameters for this were: TE 1.48ms, TR 3.0ms, flip angle 
45°, field of view 320 to 420mm depending of patient size, spatial resolution 2.0 x 
1.71 x 8mm, 50 cardiac phases.  Each patient’s blood pressure was taken non-
invasively at the same time as this axial cine acquisition. 
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2.4. Tissue Tagging 
Tissue tagging images were obtained for myocardial strain analysis.  A spatial 
modulation of magnetization pulse sequence was used and obtained in the same 
short axis planes as the stress and rest perfusion sequences, planned using a ‘3 of 
5 approach’ from the long axis cine acquisitions.  Scan parameters were: spatial 
resolution 1.51 x 1.57 x 10mm, tag separation 7mm ≥ cardiac phases, typical TR 
5.8, TE 3.5ms and flip angle 10°. 
2.5. First Pass Perfusion Imaging 
First past perfusion imaging was carried out during pharmacological stress (using 
the intravenous vasodilator adenosine) and at rest.  Scan parameters for this 
aspect of the protocol were as follows: spoiled Turbo Gradient Echo, 5 x k-t Broad-
use Linear Acquisition Speed-up Technique 11 training profiles, 1.31 x 1.32 x 
10mm, pre-pulse delay 100ms, acquisition shot 123ms/slice, three short axis slices 
planned using a ‘3 out of 5’ technique from long axis cine images (figure 2-2). 
 
Figure 2-2 3 out of 5 technique for CMR perfusion 
 
Panel A shows VLA (vertical long axis) (upper) and 4Ch (4-chamber) (lower) at end 
systole with 5 short axis slices.  Panel B shoes 5 short axis slices planned parallel 
to the MV (mitral valve) annulus with slice gap altered ensuring most basal slice is 
positioned on the MV annulus and the most apical slice at the LV apex.  Panel C 
shows resulting short axis slice positions after reducing number of slices to 3.
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Intravenous adenosine was infused via a cannula in the antecubital fossa at an 
initial rate of 140µg/kg min with continuous ECG monitoring for 3 minutes and non-
invasive blood pressure monitoring every 2 minutes.  Adequate haemodynamic 
response was assumed when any one of the following was achieved: 1) Rise in 
heart rate ≥10% above baseline heart rate, 2)  systolic blood pressure decrease 
≥10mmHg or, 3) symptoms consistent with adequate adenosine response including 
shortness of breath, chest tightness etc.  If this was not achieved at 140µg/kg min, 
the dose was increased to 170 and then 210µg/kg min (maximum dose) at 2 minute 
intervals until an adequate response was achieved. 
Contrast injection of intravenous Gadolinium-DTPA (Gadopentate dimeglumine; 
Magnevist, Bayer, Berlin, Germany) was performed using a dual bolus technique 
via a cannula in the antecubital fossa.  The initial (dilute) bolus concentration was 
0.01mmol/kg followed by the main bolus of 0.1mmol/kg, both infused at a rate of 
4.0ml/s using a saline flush injected via power injector (Spectris, Solaris, 
Pennsylvania, USA). 
2.6. Late Gadolinium Enhancement Imaging 
Late Gadolinium enhancement imaging was performed 10-15 minutes after the rest 
perfusion acquisition using inversion recovery prepared gradient echo.  A modified 
Look-Locker (MOLLI) approach was used to determine the optimal inversion time 
(ms) required to adequately null the LV myocardium.  Typical parameters were: TE 
2.0ms, TR 3.5ms, flip angle 25°, spatial resolution 1.54 x 1.76 x 10mm.  This was 
performed in 10-14 short axis slices (identical to the LV cine stack) with additional 
2Ch/4Ch ± phase swap slices acquired when required. 
2.7. T1 Mapping 
A single short axis slice at mid LV level was used for pre and post contrast T1 
mapping using an electrocardiogram-triggered MOLLI scheme.  The pre-contrast 
scheme used was a 3-3-5 acquisition with 3 R-R  interval recovery epochs) 
acquired at end-expiration (single breath hold) with a trigger delay at end-diastole.  
Scan parameters were: voxel size 1.7 x 2.14 x 10, flip angle 35° and field of view 
320-420mm depending on patient size. 
The same mid LV slice was used for post contrast T1 maps.  These were acquired 
15 minutes after the rest perfusion acquisition using the identical MOLLI scheme 
detailed above.   
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2.8. Post processing CMR analysis 
CMR analysis in chapter 5 was conducted by 2 operators (GF and PS), each with 2 
or more years’ experience in CMR analysis.  CMR analysis in chapters 6 and 7 was 
conducted by 2 operators (GF and BE) each with 2 or more years’ experience in 
CMR analysis.  All post-processing CMR analysis was carried out using the same 
software (CVI42, Circle Cardiovascular Imaging, Calgary, Canada) with the 
exception of tissue tagging analysis which used separate software (inTag version 
1.0, Creatis, Lyon, France). 
2.9. Assessment of left ventricular function 
Left ventricular endocardial and epicardial borders were manually contoured from 
the short axis LV cine stack at both end systole and end diastole in order to 
generate LV end systolic and end diastolic volumes according to the summation of 
discs methodology(182).  LV ejection fraction was derived from the equation:  
Equation 2 LV ejection fraction 
100*)/)(((%) LVEDVLVESVLVEDVLVEF   
Where EDV= end diastolic volume(ml), ESV= end systolic volume 
Both trabeculation and papillary muscles were excluded.  LV mass values were 
calculated from the end diastolic myocardial volume according to established 
methods(183).   
2.10. Assessment of right ventricular function 
Right ventricular volumes and RVEF were calculated from the short axis LV cine 
stack in a similar fashion to LV volumes and LVEF(184).  RV endocardial borders 
were manually contoured at both end systole and end diastole generating RV end 
systolic and end diastolic volumes excluding trabeculation from these values.  RV 
ejection fraction was derived from the equation: 
Equation 3 RV Ejection fraction 
100*)/)(((%) RVEDVRVESVRVEDVRVEF 
 
 Where EDV= end diastolic volume(ml), ESV= end systolic volume 
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2.11. Assessment of aortic distensibility and other 
measures of aortic stiffness 
The dedicated axial short axis cine of the descending aorta was used to calculated 
aortic distensibility (fig 2-3).  The endovascular: blood pool interface of the 
descending aorta was manually traced at its minimum volume in diastole as well as 
its maximal volume during systole to generate maximal and minimal cross sectional 
volumes.   
 
Figure 2-3 Calculation of cross-sectional descending aortic area for 
measures of artic stiffness 
 
The blue ROI traces the endovascular: blood pool interface to calculate cross 
sectional area 
 
 
Measures of aortic stiffness including aortic distensibility, aortic compliance and 
aortic stiffness (β) were calculated according to established methods(185) using the 
following equations: 
Aortic distensibility: 
 Δ relative aortic cross sectional area CSA /  Δ systolic and diastolic blood pressure 
Equation 4 Aortic distensibility 
)/(max))/min)max(( DBPSBPCSACSACSA 
 
Where CSAmax= maximum cross sectional area (cm), CSAmin= minimum cross sectional area (cm), 
SBP = systolic blood pressure (mmHg) and DBP= diastolic blood pressure (mmHg) 
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Aortic compliance: 
Δ absolute aortic cross sectional area /  Δ systolic and diastolic blood pressure 
Equation 5 Aortic compliance 
)/(min)max( DBPSBPCSACSA 
 
Where CSAmax= maximum cross sectional area (cm), CSAmin= minimum cross sectional area (cm), 
SBP = systolic blood pressure (mmHg) and DBP= diastolic blood pressure (mmHg) 
Aortic stiffness index (β): 
Ratio of the natural logarithm of systolic BP/diastolic BP to the relative change in 
aortic cross sectional area  
Equation 6 Aortic stiffness index 
max)/min)max/(()/ln( CSACSACSADBPSBP 
 
Where: CSAmax = maximum aortic cross sectional area, CSAmin = minimum aortic cross sectional area, 
SBP = systolic BP, DBP = diastolic BP, ln = natural logarithm 
 
Intraobserver reproducibility for both maximum and minimum cross sectional area 
of  the descending aorta at 3.0T was assessed between two observers (GF and 
BE) by calculating coefficient of variation (CoV).  Maximum and minimum values 
were calculated from a total of 12 randomly selected scans.  CoV for maximum 
cross sectional area of the descending aorta was 1.92% while CoV for minimum 
area was 1.72%. 
 
2.12. Assessment of tissue tagging parameters 
Tissue tagging analysis was performed on each of the 3 short axis acquisitions of 
the left ventricle (LV base, mid and apical slices).  Endocardial and epicardial 
borders were drawn using a semi-automated process using dedicated software 
(inTag version 1.0, Creatis, Lyon, France).  The software then tracked grid tags for 
each acquired slice throughout systole and diastole.  Peak circumferential strain 
and rotation were calculated for each of the 3 acquired slices.  LV twist was 
calculated by subtracting basal from apical rotation. LV torsion was calculated using 
the following equation(186):  
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Equation 7 LV torsion 
)2/())()(( LVlengthxsBASALradiuusAPICALradixionBASALrotattionAPICALrotaTSA   
Where TSA= torsion sheer angle 
 
Apical radius and basal radius were calculated from the area of the apical and basal 
slices at end diastole.  Length was calculated by subtracting the slice locations of 
the apical and basal slices and converting to centimetres.  Other definitions for LV 
torsion exist(187), however, when torsion is referred to in this thesis, it is defined as 
per the above equation, 
 
2.13. Assessment of T1 relaxation times and 
myocardial extracellular volume fraction 
Precontrast ‘native’ as well as 15 minutes post contrast myocardial and blood pool 
T1 values were recorded from the mid ventricular slice.   Care was taken when 
selecting the region of interest in the interventricular septum to avoid including 
adjoining areas of tissue or blood pool which may have given erroneous values due 
to partial volume effect.  Care was also taken when selecting the blood pool region 
of interest to avoid inclusion of any papillary muscle which may again have 
generated spurious values (figure 2-4).  The septum was chosen as this is arguably 
the most reproducible area of the LV to assess.  A potential disadvantage of this 
method (as opposed to alternatives such as taking numerous values throughout the 
LV is that localised areas of high or low T1 may be missed. 
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Figure 2-4 Calculation of T1 values 
 
The pink circular ROI provides the blood pool T1 value whereas the blue ROI 
provides the myocardial T1 value.  Corresponding values are shown at the foot of 
the image. 
 
Both native and post contrast myocardial and blood T1 values were combined with 
a  venous haematocrit (Hct) value to calculate estimated myocardial ECV fraction 
according to the following equation: 
Equation 8 ECV calculation 
ECV = (1 – Hct) x (1/myocardial post contrast T1(ms)) – (1/myocardial native T1(ms)) 
            ((1/blood post contrast T1(ms)) – (1/blood pre contrast T1(ms)) 
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Intraobserver reproducibility for both native and post contrast T1 values was 
assessed between two observers (GF and BE) by calculating coefficient of variation 
(CoV).  T1 values were assessed on 12 randomly selected scans by each observer.  
CoV for native T1 was 2.49% and for 2.38% for post contrast T1 values.  
Intraobserver reproducibility for ECV was also assessed by the same observers by 
calculating COV for ECV from 12 randomly selected scans.  CoV for ECV was 
6.46%. 
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3. Methodology for the development of ‘synthetic’ 
extracellular volume fraction at 1.5T and 3.0T 
3.1. Background 
Myocardial extracellular volume fraction assessed by cardiovascular magnetic 
resonance estimates the proportion of myocardial extracellular space relative to its 
cellular component.  This may be beneficial in the diagnosis and prognostication of 
cardiomyopathic processes.  Conventionally, ECV calculation requires knowledge 
of the patient’s haematocrit. Treibel et al.(188) recently demonstrated a ‘synthetic 
ECV’ can be calculated by estimating Hct from the longitudinal relaxivity (R1 = 
1/T1) of blood. This eliminates the time and cost of obtaining a venous Hct sample, 
as well as automated generation of in-line ECV maps akin to T1 and T2 maps. So 
far, synthetic ECV has only been described for data acquired with a single vendor 
(Siemens) and field strength (1.5 Tesla).  As such this study applies this novel 
technique for the first time at 3.0 Tesla field strength and for the first time on a 
Philips platform.  
3.1.1. Hypothesis and aims  
We hypothesised synthetic ECV can also be derived on a Philips CMR platform and 
at 3.0 Tesla, potentially broadening applicability of this method.  
This study aimed to derive linear regression equations for the correlation of blood 
pool T1 value with laboratory and test these equations in the estimation of synthetic 
ECV in a validation cohort as well as against a previously published equation. 
3.2. Methods 
The patient population for chapter 3 ‘Methodology for the development of a 
synthetic extracellular volume fraction’ included a total of 421 patients scanned for 
clinical or research purposes at Leeds General Infirmary, UK between February 
2012 and July 2016.  These patients were retrospectively recruited and 203 were 
scanned at 1.5T (Philips, Ingenia, Best, The Netherlands) and 218 were scanned at 
3.0T (Philips, Achieva, Best, The Netherlands). The 1.5T cohort comprised 47 
patients with valvular heart disease (either aortic stenosis or mitral regurgitation) 
and 44 with ST-segment elevation myocardial infarction and 112 patients 
undergoing CMR for acute clinical reasons.  The 3.0T cohort comprised 26 healthy 
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controls, 159 rheumatoid arthritis and 33 hypertrophic cardiomyopathy patients. The 
sample size was based on similar population sizes in a previous study.  The  
Patients on both scanners were randomly split into equally-sized derivation and 
validation subgroups.  Derivation groups served to enable derivation of linear 
regression equations for the relationship of Hct and R1 of blood.  This equation was 
used to calculate synthetic ECV and assess its correlation with conventionally 
calculated ECV in the validation groups.   
Bland Altman analyses were conducted to assess bias between laboratory and 
synthetic Hct and ECV values at both field strengths.  Further Bland Altman 
analysis of bias between Siemens and Philips 1.5T synthetic ECV regression 
equations was also conducted. 
Modified Look-Locker Inversion Recovery acquisition schemes were used to 
acquire T1 maps produced using vendor software prior to and 15 minutes after 
administration of either 0.2 mmol/kg Gadopentate Dimeglucide (Magnevist, Bayer 
Schering) or 0.15 mmol/kg Gadobutrol (Gadovist, Bayer Schering).  For all 1.5T 
patients, a pre-contrast 5s(3s)3s and post-contrast 4s(1s)3s(1s)2s scheme was 
used to reduce heart rate dependence of T1 values.  For all 3.0T patients the same 
3(3s)3(3s)5 scheme was used pre and post-contrast.   T1 values were derived by 
drawing a region of interest (ROI) within the interventricular septum and blood pool 
at mid-ventricular level using post-processing software (CVI 42, Circle 
Cardiovascular Imaging Calgary, Canada).  Scar was included within the 
interventricular septum ROI when present.  Analysis was blinded.  ECV was 
calculated as has previously been reported(188).  Statistical analyses were 
performed using SPSS version 22 (IBM Corporation, Armonk, New York, USA). All 
results are presented as mean ± standard deviation.  
3.2.1. Ethical approval: 
All patients gave written informed consent and the study was conducted according 
to the declaration of Helsinki.  The patients included in the study were recruited 
from a number of different studies covered by the following National Research 
Ethics Committee approvals: 10/H1307/138, 12/YH/0169, 08/H1307, 14/SC0190 &      
12/YH/0551.  
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3.3. Results 
Patient baseline demographics are summarised in table 3-1 for 1.5T patients and 
table 3-2 for 3.0T patients respectively.  There was a broad range of Hct in both 
1.5T and 3.0T derivation groups (0.41±0.05, range 0.27 to 0.53 at 1.5T and 
0.42±0.04, range 0.31 to 0.54 at 3.0T).  There was also a broad range of blood pre-
contrast T1 in 1.5T and 3.0T derivation groups (1608±105 ms, range 1402 to 1912 
ms at 1.5T and 1780±99ms, range 1457 to 1993 ms at 3.0T).  The conventionally 
calculated ECV in the validation groups was 32±9 % (range 19 to 77%) for 1.5T and 
29±5 % (range 20 to 53%) for 3.0T.   
Table 3-1 Baseline Demographics for 1.5T patients 
Variable Derivation Group 
(n=102) 
Validation Group 
(n=101) 
Combined groups 
(n=203) 
Male gender  66/102 (65%) 70/101 (69%) 136/203 (67%) 
Age (years) 65±17 58±18 61±18 
Systolic BP (mmHg) 140±25 129±25 134±25 
Diastolic BP (mmHg) 76±29 77±19 77±20 
LVEF (%) 52±13 48±15 50±14 
Creatinine (mmol/L) 80±23 87±35 83±30 
Haemoglobin  133±18 132±21 132±20 
Haematocrit 0.41±0.05 0.40±0.06 0.41±0.06 
Myocardial native T1 (ms) 1038±95 1052±82 1045±88 
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Table 3-2 Baseline demographics for 3.0T patients 
Variable Derivation Group 
(n=109) 
Validation Group 
(n=109) 
Combined groups 
(n=218) 
Male gender  47/109 (43%) 54/109 (50%) 101/215 (46%) 
Age (years) 49±14 48±18 48±16 
BMI (kg/m2) 26±4 26±5 26±4 
Systolic BP (mmHg) 123±16 119±14 121±15 
Diastolic BP (mmHg) 71±12 67±12 69±12 
LVEF (%) 61±6 60±5 60±6 
Creatinine (mmol/L) 69±16 66±14 68±15 
Haemoglobin  140±13 135±12 138±13 
Haematocrit 0.42±0.04 0.42±0.04 0.42±0.04 
Myocardial native T1 (ms) 1190±53 1185±58 1187±56 
 
 
The regression lines between Hct and R1 blood were linear at both field strengths 
(1.5T: R2= 0.50, p = <0.001; 3T: R2= 0.46, p= <0.001), with the following regression 
equations (Figure 2-2): 
 
Equation 9 Synthetic ECV regression equation at 1.5T 
0.1668 - ])[1/T1blood · (922.6 = MOLLIHct  Synthetic  
 
Equation 10 Synthetic ECV regression equation at 3.0T 
0.071 - ])[1/T1blood · (869.7 = MOLLIHct  Synthetic  
Where Hct is haematocrit (between 0 and 1) and R1blood is 1/T1blood in milliseconds  
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Using these equations to calculate synthetic ECV in both validation cohorts, 
conventional and synthetic ECV were highly correlated (Figure 3-1) (R2= 0.95, p= 
<0.001 at 1.5T and R2= 0.92, p= <0.01 at 3.0T). 
 
Figure 3-1 Linear correlation and regression equations between blood Hct 
and Blood R1 at 1.5T and linear correlation between blood and synthetic 
ECV 
 
Panel A: linear correlation and regression equations between blood Hct and 
blood R1 at 1.5T and 3.0T (Panel B).  Linear correlation between conventional 
and synthetic ECV at 1.5T (Panel C) and 3.0T (Panel D). 
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On Bland-Altman analysis (figure 3-2), synthetic ECV demonstrated minimal bias at 
both 1.5T (bias= -0.81%, 95% C.I.-4.97–3.35%) and 3.0T (bias= -0.30%, 95% C.I.-
3.92–3.33%) i.e. synthetic ECV was lower than laboratory ECV. 
Figure 3-2 Bland Altman analysis of bias between conventional and 
synthetic ECV 
 
Panel A: 1.5T and panel B: 3.0T 
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Bland Altman analysis of synthetic haematocrit versus laboratory haematocrit 
showed a slight negative bias (i.e. values were lower for synthetic versus laboratory 
ECV) at 1.5T and minimal bias at 3.0% (figure 3-3).  Mean bias at 1.5T was -0.017, 
95% C.I.  -0.10 – 0.061) and mean bias at 3.0T was -0.003, 95% C.I. -0.075 – 
0.068).  
 
Figure 3-3 Bland Altman analysis of bias between laboratory and synthetic 
Hct 
 
Panel A shows bias between laboratory and synthetic Hct at 1.5T and panel B 
shows bias between bias between laboratory and synthetic Hct at 3.0T 
 
- 47 - 
 
 
Correlation between conventional ECV and synthetic ECV calculated using both the 
regression equation from the 1.5T derivation cohort and the 1.5T MOLLI synthetic 
ECV equation reported by Treibel et al.(188) is shown in figure 3-4. 
 
Figure 3-4 Correlation between conventional and synthetic ECV at 1.5T 
using alternative regression equation 
 
 
On Bland-Altman analysis, ECV values calculated in the validation cohort using 
Treibel’s 1.5T MOLLI synthetic ECV equation showed minimal negative bias of 
0.4%, 95% C.I. 0.06- 0.73% in comparison to ECV calculated the synthetic ECV 
equation from this study. 
 
3.4. Discussion 
We have demonstrated that synthetic ECV, derived by estimating Hct from pre-
contrast blood T1 values acquired with a MOLLI method on 1.5 and 3T Philips 
systems, strongly correlates with conventionally calculated ECV.  The correlation 
values demonstrated between Hct and R1 blood in the derivation cohort and 
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between conventional and synthetic ECV in the validation cohort are similar to 
those reported in the Treibel et al. on a Siemens platform using both MOLLI and 
shortened MOLLI (ShMOLLI) pulse sequences.   
Correlation between between laboratory and synthetic Hct was moderate at both 
field strengths with a negative bias of -0.017 at 1.5T and very minimal bias of 0.003 
at 1.5T.  There have been early reports of poor agreement of laboratory and 
synthetic Hct values, particularly with very low or very high Hct as are seen in 
conditions such as iron deficiency anaemia and dehydration respectively(189).  
Known factors which may contribute to this include variability in the laboratory Hct 
measurement in itself, as well as blood flow and body temperature(188).  This was 
apparent to some degree in the 1.5T derivation cohort in this study, who had a wide 
range of Hct values, but less apparent in the 3.0T derivation cohort who had a 
narrower range of Hct values which were predominantly within the normal range.  
However, overall this did not lead to significant accuracies in synthetic ECV 
calculation and the technique appears to offer robust and accurate ECV estimation 
across a wide range of ECV values. 
These findings and synthetic ECV equations could be applied to other Philips 1.5 
and 3.0T identical to those used in this study, although ideally local regression 
equations using similar sized derivation and validation populations to ensure 
accuracy of synthetic ECV.  We have demonstrated that our own 1.5T synthetic 
ECV equation showed excellent agreement with the corresponding equation 
derived on an alternative vendor platform using a comparable MOLLI pulse 
sequence.  Although ideally such equations should be locally calibrated (as T1 
values are dependent on vendor platform), the apparent small differences and 
minimal bias between synthetic ECV values generated by the two equations this 
gives an indication that universal adoption of the equations we have produced in 
this study would be unlikely to lead to significant imprecision in synthetic ECV 
calculation.  Nevertheless, in this study we have not assessed whether our 3.0T 
synthetic ECV equation is valid on an alternative vendor platform. 
Key areas for future work in the area of synthetic ECV should focus on three key 
areas.  Firstly, there appears to some discrepancy between laboratory and 
synthetic Hct values at the lower and higher range. Further work is required to 
determine why this occurs and, importantly whether any steps can be taken to 
control any responsible factors and thereby improve accuracy of Hct estimation.  
Secondly, it remains unclear as to the applicability of the synthetic ECV equations 
produced in this study across alternative vendor platforms.  A future study may 
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validate this equation on an alternative vendor platform at 3.0T.  Finally, the clinical 
impact of synthetic ECV, particularly the generation of in-line ECV maps in 
improving the diagnosis and prognostication of cardiomyopathy as well as 
improvements in clinical workflow has yet to be studied. 
3.5. Conclusion 
This study underscores the accuracy of synthetic ECV and highlights its 
applicability across platforms and both 1.5 and 3.0T field strengths.  It offers the 
potential for use on a routine clinical CMR list, eliminating the need for a venous Hct 
sample, enabling rapid clinical decision-making. 
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4. Methodology for the development of aortic and 
circumferential strain analysis using CMR feature tracking 
4.1. Background 
Aortic stiffness has been proposed as a surrogate marker of generalised 
atherosclerosis with the potential to identify patients at increased risk of CVD, 
potentially offering improved CVD risk estimation than standard clinical scoring 
calculators.  Aortic strain analysis has emerged as a promising technique which 
appears more sensitive than traditional methods in detecting age-related changes 
in vascular performance(190) and may therefore offer enhanced and more accurate 
CVD risk estimation than existing techniques.  Aortic strain has never been 
described using CMR, thus this study aims to develop this promising and novel 
technique for assessment of aortic stiffness. 
Studies using echocardiographic speckle tracking have measured circumferential 
and radial strain in vivo, providing normal values(191, 192) and demonstration of 
lower values in atherosclerotic disease(193).  Circumferential values in particular 
show promise in identifying patients with significant atherosclerotic disease, who 
are likely to be the patients at the very highest risk of CV events.  Kim et al. 
demonstrated a correlation between carotid circumferential strain values and the 
presence or absence of coronary artery atherosclerotic disease on coronary 
angiography(194).  In the same study, carotid intima-media thickness showed no 
significant correlation with coronary artery disease.  Similarly, Podgorski et al. 
demonstrated a significant negative correlation between carotid circumferential 
strain values and calcium score, not seen with carotid distensibility or β1 stiffness 
index(195).  These studies highlight the attractiveness of assessing strain values in 
large arteries and their potential to offer more clinically relevant information than 
other measures of vascular performance. 
CMR-FT is a post-processing technique which works by recognising patterns of 
features or regularities within a specified region of interest on a series of cine 
imaging(32).  The software tracks and follows these irregularities through time and 
space, thereby producing deformation parameters.   This technique is very similar 
conceptually to echocardiography speckle tracking, hence CMR-FT has the 
potential to calculate the same arterial strain indices assessed using 
echocardiography speckle tracking with the added advantage of unlimited imaging 
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planes inherent to CMR cine imaging and without the need for additional 
acquisitions.  
4.1.1. Hypothesis and aims 
No study to date has demonstrated aortic strain analysis using cardiovascular 
magnetic resonance imaging.  We hypothesised that CMR-FT post-processing 
software can be used to determine ascending and descending aortic strain from 
SSFP cine acquisitions. 
This study aimed to assess the feasibility and reproducibility of assessing aortic 
strain parameters using CMR-FT in a group of healthy volunteers with no prior 
history of cardiovascular disease.   
4.2. Methods 
The patient population for chapter 4 ‘Methodology for the development of aortic 
radial and circumferential strain analysis using CMR feature tracking’ included 10 
consecutive healthy volunteers recruited between March 2016 and February 2017.  
All volunteers were scanned at 3.0T (Philips, Achieva, Best, The Netherlands) at 
Leeds General Infirmary, UK and had no history of CV disease (cardiac, peripheral 
or cerebral) and no significant past medical history were recruited to undergo CMR 
examination.  
Interobserver, intraobserver and interstudy reproducibility values were calculated by 
analysing CoV for ascending and descending aorta radial and circumferential strain.  
For interstudy reproducibility, separate CMR studies were carried out on the same 
healthy controls 7 days apart.  To test reproducibility values at lower and higher 
temporal resolutions, standard 50-phase cine and higher temporal resolution 100-
phase acquisitions for the descending aorta were obtained.  The sample size of 10 
was chosen on the basis of this representing the minimum acceptable number of 
samples from which to provide an indication of reproducibility(196).    
Mean time taken to analyse both ascending and descending aortic strain as well as 
mean breath hold time for cine acquisitions was assessed. 
In each patient, an axial bSSFP cine acquisition (bSSFP, multiphase, single 
imaging slice, spatial resolution 2.0 x 1.71 x 8mm, 50 cardiac phases) was acquired 
of the ascending and descending thoracic aorta at the level of the main pulmonary 
artery.  An additional axial bSSFP cine acquisition was obtained in an identical 
imaging plane at higher temporal resolution using parallel imaging to maintain an 
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identical resolution and breath hold time (bSSFP, multiphase, single imaging slice, 
spatial resolution 2.0 x 1.71 x 8mm, 100 cardiac phases).     
The endothelial border and outer wall of the descending and ascending was 
contoured at end diastole (figure 4-1 on following page) using dedicated post-
processing software (CVI 42, Circle Cardiovascular Imaging Calgary, Canada).  
The software then tracked movement of the aortic endothelial border and aortic wall 
through time and space to produce radial and circumferential strain values. 
 
 
 
 
Figure 4-1 Descending aortic strain values generated by CMR FT 
 
Panel A shows contouring of the outer aortic wall and endothelial borders at end 
diastole.  Panel B shows the automated generation of strain values.  Panel C shows 
the resultant circumferential strain curve (y axis =strain (%) and x axis = time (ms). 
 
4.2.1. Ethical approval: 
All patients gave written, informed consent to take part in the study and the study 
was conducted according to the declaration of Helsinki.  The study was approved 
by the National Research Ethics Committee (12/YH/0551). 
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4.3. Results 
Demographics of all study participants and results of strain analysis for both the 
ascending and descending aorta as well as for both radial and circumferential strain 
by CMR-FT are presented in table 4-1 (following page).  Reproducibility values 
(coefficient of variation) for both ascending and descending aorta and both radial 
and circumferential strain are summarised in table 4-2 (following page).   
 
4.3.1. Reproducibility of ascending and descending aortic 
strain 
Both radial and circumferential values for the descending aorta were most 
consistent in terms of intraobserver, interobserver and interstudy with similar 
coefficient of variation values in the region of 10% obtained at lower (50 phase cine 
acquisition) and higher temporal resolution (100 phase cine acquisition).  For these 
acquisitions, the same amount of data was acquired as for 50 phase acquisitions, 
and was split into 100 rather than 50 ‘bins’. 
Similarly, intraobserver, interobserver and interstudy reproducibility values for radial 
and circumferential strain of the ascending were excellent at lower temporal 
resolution (coefficient of variation <10% for all values).   
However, reproducibility at higher temporal resolution gave a coefficient of variation 
of 14.5 and 17.6 for radial and circumferential strain respectively. 
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Table 4-1 Baseline demographic data for healthy volunteers 
Baseline Characteristics  
 Healthy volunteers 
Number (men) 10 (6) 
Age 40 ± 10 
Systolic blood pressure (mmHg) 119 ± 11 
Diastolic blood pressure (mmHg) 63 ± 7 
 
 
Table 4-2 Reproducibility measurements for aortic strain in healthy 
volunteers 
Reproducibility 
Measurements  
    
 Intraobserver 
Coefficient of 
Variability 
(%)  
Interobserver 
Coefficient of 
Variability 
(%) 
Interstudy 
Coefficient 
of Variability 
(%) 
50 versus 100 
phase 
acquisition 
Coefficient of 
variability (%) 
Ascending aorta 
Radial strain 4.8 8.0 8.3 14.5 
Circumferential strain 6.5 9.4 8.3 17.6 
Descending aorta 
Radial strain 7.1 8.6 9.5 10.3 
Circumferential strain 8.5 10.7 12.3 12.3 
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4.3.1. Feasiblity of aortic strain by CMR-FT 
Mean breath hold time (± standard deviation) for cine acquisitions (50 and 100 
phase cine acquisitions) was 12 ± 2 seconds.  
Mean time to taken to calculate circumferential and radial strain using post-
processing software (± standard deviation) was 58 ± 12 seconds. 
 
 
4.4. Discussion 
In this first study assessing the measurement of novel radial and circumferential 
strain values using CMR-FT, we have demonstrated two key findings.  Firstly, 
measurement of strain values using CMR-FT is feasible, requiring a short breath-
held cine acquisition and a simple and short analysis time using post-processing 
software.  Secondly, the technique used to assess strain values is highly 
reproducible for both circumferential and radial strain values, with the most 
reproducible values obtained in the descending aorta as opposed to the ascending 
aorta.  
Our finding of a mean breath-hold time for all cine acquisitions (both 50 and 100 
phase bSSFP) of 12 ± 2 seconds compares favourably with other CMR acquisitions 
and should be achievable for most patients undergoing CMR examination.  
Although not used in this study, a ‘respiratory navigator’ allowing free-breathing of 
the patient during the acquisition could be used in patients unable to breath-hold for 
the required period of time.  This is a standard feature on most built-in scanner 
software  where data is only acquired when the patient’s diaphragm is within a pre-
defined image location, although overall scan time increases markedly.  The mean 
post-processing analysis time of 58 ± 12 seconds we report was short and 
compares favourably with other CMR post-processing applications.  This, coupled 
with the short mean breath hold time for the cine acquisition of the descending 
aorta, indicate assessment of aortic strain using CMR-FT requires straightforward 
analysis and adds very little time to any CMR protocol.  This consideration is 
important for any emerging imaging parameter, particularly is it is to be adopted into 
routine clinical use.  Although other validated techniques for the assessment of 
aortic stiffness using modalities other than CMR, CMR involves no ionising radiation 
and offers the opportunity to combine numerous other quantitative indices (which 
may further aid assessment of subclinical CVD) in one scan taking less than 1 hour. 
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Reproducibility for both radial and circumferential strain was comprehensively 
assessed in this study using coefficient of variation for Intraobserver, interobserver 
and interstudy reproducibility, as well as reproducibility between lower and higher 
temporal resolution cine acquisitions.  This demonstrated good reproducibility for 
both radial and circumferential strain which was most consistent within the 
descending aorta.  Reproducibility in the ascending aorta was less consistent, 
particularly between lower and higher temporal resolution acquisitions.   
The reason for this discrepancy may relate to one or both of two factors.  There is a 
higher degree of through-plane motion of the ascending aorta compared with the 
descending aorta as it shortens and lengthens along its long axis in systole and 
diastole respectively.  This may have led to difficulties in the software tracking the 
correct features within the specified region of interest at the endothelial border.   
A second potential explanation for the discrepancy of ascending aorta strain values 
obtained from higher and lower temporal resolution images could be the concept of  
‘flow artefact’ due to dephasing of magnetisation in areas of high velocity blood flow 
which was more prominent within the ascending versus descending aorta.  Areas of 
dephasing within the ascending aorta may have been erroneously tracked by the 
post-processing software in preference to the endothelial border of the aorta 
leading to inaccuracy in the strain values obtained.   
Flow artefact is increased at higher field strengths and can be reduced (although 
frequently not eliminated) by changing the phase-encoding direction of image 
acquisition and careful ‘shimming’ of images to ensure homogeneity of 
magnetisation within the desired imaging plane.  Although in this study we elected 
to use a 3.0T field strength to scan patients, it is possible that reproducibility for 
aortic strain using CMR-FT may be improved at 1.5T given the likelihood that the 
potential source of inaccuracy relating to flow artefact would be reduced.  
Future studies should assess the feasibility and reproducibility of aortic strain using 
CMR-FT at 1.5T, which may provide improved reproducibility, particularly within the 
ascending aorta.  Furthermore, the utility of aortic strain in assessing vascular 
performance should be assessed in pathologic disease states associated with 
increased risk of developing CVD to assess its performance against other 
established measures of vascular performance. 
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4.5. Conclusion 
We have demonstrated that CMR-FT of the ascending and descending aorta is 
feasible with good interobserver, intraobserver and interstudy reproducibility.  
Reproducibility for strain values excellent and  is most consistent in the descending 
aorta with good reproducibility between standard and higher temporal resolution 
cine acquisitions.   
Further study is required to assess the technique in a larger population size and to 
assess its ability to detect changes in arterial stiffness in populations at increased 
CVD risk as well as against established alternative measures of aortic stiffness.  
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5. The Utility of Global Longitudinal Strain in the 
Identification of Prior Myocardial Infarction in Patients 
with Preserved Left Ventricular Ejection Fraction 
5.1. Background 
Prior myocardial infarction is defined as either the presence of pathological Q 
waves on an ECG, regional loss of myocardium on CV imaging in the absence of a 
non-ischaemic cause or pathological findings supportive of prior MI(95).   
Myocardial infarction is frequently unrecognised at the time of its occurrence, 
accounting for 20-40% of all prior MI in high risk populations diagnosed on  ECG 
criteria(197, 198).  Cardiovascular magnetic resonance LGE imaging offers a more 
sensitive means of diagnosis than ECG and is considered the reference standard 
non-invasive imaging technique for the detection of prior MI(10, 13).  Studies using 
this approach have suggested that unrecognised MI is more common than 
recognised prior MI in certain populations, with a prevalence of 18% in an elderly, 
community-based cohort(199).  
The presence of unrecognised MI detected by LGE is associated with a ten-fold 
increase in risk of CV mortality, which appears to be incremental to conventional 
clinical and imaging risk factors(115).  Recognition of the condition is therefore 
important and secondary prevention therapy aimed at reducing long-term CV risk is 
recommended when prior MI is diagnosed(124). 
In patients undergoing echocardiography as opposed to CMR or patients with 
kidney disease precluding the use of Gadolinium based contrast agents, diagnosis 
of prior MI traditionally relies on the assessment of radial measures of LV systolic 
function.  Indicators suggestive of prior MI include regional wall motion abnormality 
(hypokinesis, akinesis or dyskinesis of 2 or more contiguous LV segments) with or 
without reduction in LVEF.  However, the relative diagnostic accuracy of both 
regional wall motion abnormality and LVEF in correctly identifying prior MI are not 
known. 
Longitudinal strain parameters theoretically have the potential to detect prior MI.    
Myocardial fibres situated in the LV subendocardium contribute significantly to 
longitudinal LV contraction in systole(200).  These fibres are susceptible to 
ischaemia and increased wall stress(201) and hence, prior MI affecting these fibres 
may lead to reductions in longitudinal strain values(202).  GLS is a summation of 
myocardial deformation in the longitudinal plane during systole(22).  It is proposed 
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to detect subclinical LV systolic function in a number of cardiomyopathies where LV 
ejection fraction (LVEF) is preserved(24).  Global longitudinal strain rate (GLSR) 
and early diastolic longitudinal strain rate (GLSRe) represent the rate of longitudinal 
systolic and early diastolic deformation(22) and are comparable to tissue Doppler 
derived S prime and E prime measurements(203).  CMR feature tracking is an 
alternative method of measuring these and other myocardial strain indices and uses 
post-processing software to rapidly obtain measurements from SSFP cine imaging.   
GLS has been demonstrated to be reduced in patients with HF-REF due to chronic 
ischaemic heart disease(204) and in the setting of acute MI(25).  However, GLS in 
patients with MI but preserved LVEF has not yet been investigated. 
 
5.1.1. Hypothesis and Aims 
This chapter aimed to assess the performance of 3 longitudinal strain parameters 
(GLS, global longitudinal strain rate and early diastolic strain rate) measured by 
CMR-FT in correctly diagnosing the presence of prior myocardial infarction in a 
group of patients with this condition and a group of healthy controls.  
We hypothesised that patients with prior MI detected by LGE but preserved LVEF 
would have impaired GLS and longitudinal strain rates compared to matched 
normal controls.  Furthermore we hypothesised that these strain parameters would 
be more accurate than the standard non-invasive imaging parameter, presence of 
regional wall motion abnormality, in correctly identifying prior MI. 
5.2. Methods 
5.2.1. Study population 
The patient population for Chapter 5 “The Utility of Global Longitudinal Strain in the 
Identification of Prior Myocardial Infarction in Patients with Preserved Left 
Ventricular Ejection Fraction” included 40 consecutive clinical patients undergoing 
CMR examination recruited from and scanned at Leeds General Infirmary, UK 
between November 2012 and January 2016.  Inclusion criteria were 1) evidence of 
prior MI (defined as hyperenhancement on late Gadolinium enhancement imaging 
in a typical subendocardial distribution) and preserved LVEF (LVEF ≥55% on cine 
imaging).  Exclusion criteria included MI having occurred in the past 3 months as 
this could have affected scar burden and/or LV systolic function.  
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The healthy control population included 40 healthy controls prospectively recruited 
between September 2014 and January 2016 and matched for age and gender with 
the prior MI patient population.  These patients had no history of CV disease 
(cardiac, peripheral or cerebral).  All participants ( patients and healthy volunteers) 
were screened for CV risk factors by completion of a health questionnaire and from 
medical records. 
This was a single centre case control study involving 40 clinical patients with prior 
MI occurring > 3 months previously and preserved LVEF (≥55%) and 40 controls 
matched for age and sex with LVEF (≥55%).  Prior MI patients were retrospectively 
recruited from consecutive patients undergoing CMR for clinical reasons and 
selecting those with MI and preserved LVEF.  Although ideally patients without CVD 
risk factors would have been chosen so as to minimise the potential for these to act 
as confounding factors, this would have left an unacceptably small sample size 
given the low prevalence of prior MI in patients without these risk factors.   Healthy 
controls were prospectively recruited volunteers with no history of cardiac disease.  
All participants were screened for CV risk factors by completion of a health 
questionnaire and from medical records. 
CMR Acquisition 
All patients underwent CMR at either 1.5T (Philips Ingenia) or 3.0T (Philips 
Achieva) and controls at 3.0T (Philips Achieva).  Images were acquired with breath 
holding on end-expiration prior to contrast administration and prospectively gated 
using a 3-lead vector ECG.   
Cine images were planned from the scout images and for every patient a 2Ch, 4Ch 
and an LV short axis cine stack were acquired to ensure full coverage of the left 
ventricle.   
LGE imaging was performed in all patients with acquisitions of a short axis LV 
stack, 2Ch and 4Ch obtained 10 minutes after administration of 0.2mmol/kg 
Gadolinium DTPA contrast (Gadovist, Bayer Schering) using inversion recovery-
prepared T1 weighted echo.   
The optimal inversion time (TI) to null normal myocardial signal ascertained by the 
Look Locker approach.  Between 10 and 12 short axis LV, 2Ch and 4Ch images 
were acquired for every patient. Further imaging with altered phase-encoding 
direction or systolic imaging were acquired when prior MI was suspected after initial 
imaging.  
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5.2.1. CMR analysis 
All post processing analysis of CMR scans was performed using the same software 
(CVI 42, Circle Cardiovascular Imaging Calgary, Canada).  LV contours were drawn 
manually at both end diastole and end systole on the LV short axis SSFP cine 
stack.  LV papillary muscles were considered part of the LV cavity. 
Percentage myocardial systolic wall thickening (SWT) was calculated from the end 
diastolic and end systolic contours as previously reported (205).  SWT was 
calculated for each LV segment based on the 16 segment AHA model.  A  cut-off 
value of 30% was used to define the presence of wall motion abnormality (WMA) in 
an individual LV segment(206).  The minimum value for each of the 16 LV 
segments in each patient was taken and used for comparison between prior MI 
patients and controls.   
The presence of LGE in a subendocardial pattern suggestive of prior MI was 
determined independently by two physicians with over 4 years’ experience in CMR.  
Quantitative assessment of myocardial scar burden was performed using a 
threshold of 50% of the maximum intensity within the scar (full width half max 
method) which has been proposed as the most reproducible method for this 
purpose(207).   
After optimisation of brightness and contrast settings, manual delineation of two 
separate user-defined ROIs were made on an LGE short axis slice where infarcted 
myocardium was present.  One ROI was an area of hyperintense infarcted 
myocardium and a second ROI was drawn in remote myocardium containing no 
infarcted myocardium.  Automated calculations for the remaining LV short axis LGE 
stack based on these two ROIs were then performed.   
The strain parameters GLS, GLSR and GLSRe were calculated using feature 
tracking software from 4Ch and 2Ch SSFP cine acquisitions (figure 5-1 ). 
Prior to analysis, brightness and contrast settings were adjusted to allow 
optimisation of endocardial and blood pool differentiation.  The epicardial and 
endocardial borders were traced manually. The software then tracked the voxel 
features of the myocardium to quantify the motion of myocardium and compute 
strain values(32).  This process results in generation of values of percentage 
deformation in the longitudinal plane throughout the cardiac cycle (providing a value 
for GLS) as well as deformation rate throughout the cardiac cycle (providing values 
for GLSR and GLSRe).   
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Figure 5-1 Calculation of GLS using CMR feature tracking in a healthy 
control 
 
Panel A:  4Ch cine acquisition with manually contoured epicardial and endocardial 
borders.  Panel B: 2Ch cine acquisition with manually contoured epicardial and 
endocardial border.  Panel C: Feature tracking of 4Ch cine acquisition.  Panel D: 
Feature tracking of the 2Ch cine acquisition.  Panel E: Graph showing GLS (x axis 
shows time (ms) and y axis shows deformation (%) in longitudinal plane).  Panel F:  
Graph showing longitudinal strain rate (x axis shows time (m/s) and y axis shows 
deformation rate (%/s)). 
 
 
5.2.2. Statistical analysis and power calculation 
Normality of data was tested using a Shapiro-Wilk test.  Mean values ± SD are 
reported.  Unpaired Student t-test and Mann-Whitney U test were used as 
appropriate to compare continuous variables.  Cut-off values to identify prior MI 
were derived from receiver-operating characteristic (ROC) curve analysis using 
Youden index giving maximum sensitivity and specificity.   
Area under the curve values (AUCs) were compared by using validated methods 
described by DeLong et al(208).  Multivariable linear regression was used for 
variables with a statistical significance of < 0.1 on univariable linear regression.  
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Intra and interobserver variability for GLS were tested on 10 randomly selected 
healthy controls using coefficient of variation.  All tests were two-sided and p<0.05 
was considered statistically significant. 
Based on the pooled standard deviation of 2.8% 31 subjects are needed in each 
group to detect an absolute reduction of GLS by 2% in those with chronic MI 
(α=0.8, significance=0.05). 
5.2.3. Ethical approval: 
All patients gave written, informed consent to take part in the study.  The study was 
completed according to the declaration of Helsinki.  The study protocol was 
approved by the National Research Ethics Committee (12/YH/0169). 
 
5.3. Results 
A total of 40 prior MI and 40 healthy controls were recruited.  Analysis was 
completed in all 40 patients in both groups, thus all were included in the final study 
sample.    
The prior MI patients were well-matched with controls for age and sex.  Other 
variables including blood pressure, body mass index, LV mass, LVEDV and LV 
systolic function were comparable across both groups.  There were no statistically 
significant differences between any of these variables (table 5-1 on following page).   
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Table 5-1 Patient characteristics in patient and prior MI groups 
Clinical Variable Prior MI (n=40) Controls (n=40) p Value 
 
Age 60 ± 11 57 ± 10 0.29 
Females 9/40 (23%) 9/40 (23%) - 
LVEF (%) 62.3 ± 3.9 62.1 ± 3.8 0.82 
LV mass (g) 107.9 ± 24.6 100.7 ± 23.8 0.18 
LVEDV(ml) 159.8 ± 34.3 161.3 ± 30.2 0.84 
Systolic blood pressure (mmHg) 133 ± 25.6 130.0 ± 12.3 0.61 
Diastolic blood pressure (mmHg) 78 ± 19.5 73.0 ± 9.8 0.19 
Body mass index (kg/m2) 27.9 ± 3.4 27.8 ± 3.9 0.82 
Haemoglobin (g/L) 146 ± 11.5  142 ± 14.5 0.27 
Creatinine (micromol/L) 77 ± 13.4 75 ± 13.6 0.52 
Estimated GFR (ml/min/1.73m2) 81 ± 8.5 83 ± 9.1 0.83 
Hypertension 13/40 (33%) 4/40 (9%) 0.008 
Hypercholesterolemia 10/40 (25%) 1/40 (3%) 0.004 
Diabetes Mellitus 6/40 (15%) 0/40 0.02 
Smoking 18/40 (45%) 2/40 (6%) <0.001 
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5.3.1. Feature tracking parameters of myocardial strain 
Feature tracking analysis was successfully performed in all prior MI patients and 
controls.  Global longitudinal strain (figure 5-2 and figure 5-3) was significantly lower 
in prior MI patients than controls (-17.3 ± 3.7% versus -19.3 ± 1.9%, p=0.012).  
Global longitudinal strain rate was significantly lower in prior MI patients versus 
controls (-88.0 ± 33.7%s-1 versus -103.3 ± 26.5%s-1 p=0.005).  Early diastolic 
longitudinal strain rate was also significantly lower in prior MI patients versus 
controls (76.4 ± 28.4%s-1 versus 95.5 ± 26.0%s-1, p=0.001).   
GLS was not significantly different in prior MI patients scanned at 1.5 and 3.0T 
(mean GLS at 1.5T -18.0 ± 1.8 versus -17.2 ± 4.0 at 3.0T, p = 0.61). 
 
Figure 5-2 Example of GLS in prior myocardial infarction 
 
Panel A shows short axis cine acquisition of LV at end diastole.  Panel B shows 
short axis cine acquisition of LV at end systole with no appreciable RWMA.  Panel 
C shows LGE acquisition with subendocardial MI of basal inferolateral LV segment.  
Panel D shows resultant GLS of 14%. 
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Figure 5-3 Box and whisker plots for GLS in healthy controls and prior MI 
patients 
 
The horizontal line within the box represents the median value, the bottom line of 
the box represents the 25th centile and the top of the box the 75th centile.  The 
narrower ‘whiskers’ above and below the box represent the 95% confidence 
interval. 
 
 
 
5.3.2. Quantitative systolic wall thickening 
Quantitative systolic wall thickening analysis was possible in all prior MI patients 
and controls.  There was no significant difference in minimum SWT in those with 
prior MI compared to controls (46.0 ± 18.3% versus 42.0 ± 14.1%, p=0.093).  There 
was no significant difference in the proportion of subjects with WMA defined as a 
segment with SWT<30% (6/40 (15%) prior MI patients and 6/40 (15%) controls. 
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5.3.3. Receiver operator characteristic analysis 
AUC for the ability of each longitudinal strain parameter to correctly identify prior MI 
were as follows (figure 3-3): GLS 0.662 (95% C.I. 0.540-0.785), p=0.01, GLSR 
0.684 (95% C.I. 0.566-0.802), p=0.005 and for GLSRe 0.707 (95% C.I. 0.592-
0.821), p=0.001.  By comparison, AUC for the ability of both presence of WMA and 
minimum SWT to correctly identify prior MI were lower at 0.500 (95% C.I. 0.386 – 
0.614), p=1.0 and 0.609 (95% C.I. 0.483-0.735), p=0.09 respectively.   
Comparison of AUC values for all longitudinal strain parameters assessed showed 
significantly higher diagnostic accuracy for the detection of prior MI than WMA (GLS 
p= 0.02, GLSR p=0.01 and GLSRe p=0.001).  Comparison of AUC values between 
longitudinal strain parameters and minimum SWT showed no statistical significance 
(GLS p= 0.59, GLSR p=0.39 and GLSRe p=0.29). 
 
 
Figure 5-4 ROC curves for the accuracy of longitudinal strain parameters 
(GLS, GLSR and GLSRe) and presence of WMA in the prediction of prior 
MI 
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5.3.4. Scar quantitation 
Scar quantitation was successfully performed in all prior MI patients.  The range of 
absolute scar mass was wide at between 0.7g and 21.4g.  The overall mean 
absolute scar mass was 5.5 ± 4.3g, equating to a relative percentage of LV mass of 
4.9 ± 3.3 %.     
5.3.5. Sensitivity and specificity of feature tracking derived 
strain values 
Two approaches were used in determining sensitivity and specificity for the correct 
identification of prior MI by the different longitudinal strain values assessed.  Firstly, 
the cut-off value giving maximum area under the curve was determined for each 
variable.  Secondly, the value giving maximum specificity was determined.  Results 
are summarised in table 5-2.    
  
Table 5-2 Identification of prior MI with longitudinal strain parameters 
optimised for sensitivity and specificity 
 
 
 
 
 
Variable Sensitivity  
(%) 
Specificity 
(%) 
MI correctly 
identified  
MI Incorrectly 
identified 
GLS     cut-off >-18% 
            cut-off >-15.7% 
60 
22.5 
72.5 
100 
24/40 
9/40 
11/40 
0/40 
GLSR   cut-off >-93.5%s-1 
            cut-off >-66.4%s-1 
65 
22.5 
60 
100 
26/40 
9/40 
16/40 
0/40 
GLSRe cut-off <86%s-1 
            cut-off <44.81%s- 
67.5 
10 
60 
100 
27/40 
4/40 
16/40 
0/40 
- 69 - 
 
5.3.6. Univariable and multivariable regression analysis for 
GLS 
Variables including patient demographics, risk factors for CVD and presence of 
prior MI were analysed to determine univariable predictors of GLS (table 5-3).  
Multivariable regression analysis revealed only prior MI to be an independent 
predictor of change in GLS. 
 
Table 5-3 Univariable and multivariable regression analysis for global 
longitudinal strain 
Variable Beta 95% CI  p value 
Age  0.04 -0.03 – 0.10 0.29 
Hypertension 1.26 -0.48 – 3.00 0.15 
Hypercholesterolemia 1.84 -0.17 – 3.84 0.07 
Diabetes 0.77 -1.96 – 3.49 0.58 
Smoking (ever) 0.47 -1.16 – 2.10 0.57 
Prior MI -1.97 -3.29 - -0.65 0.004 
Systolic BP -0.01 -0.05 – 0.03 0.76 
Diastolic BP 0.02 -0.03 – 0.07 0.49 
 
Multivariable regression for Global Longitudinal Strain 
Variable Beta 95% CI  p value 
Hypercholesterolemia 0.93 -1.11 – 2.97 0.37 
Prior MI -1.94 -3.41 - -0.47 0.01 
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5.3.7. Observer variability 
On intraobserver analysis, mean GLS values by CMR feature tracking were similar 
at -20.3% and -19.6% (p= 0.60) and CoV 3.9%.  On interobserver analysis, mean 
GLS values CMR feature tracking were again similar at -20.3% and -19.6 (p= 0.62) 
and CoV% 4.0%. 
 
5.4. Discussion 
We have found that in patients with preserved LVEF and prior MI there is 
impairment of GLS, GLSR and GLSRe.  Furthermore, impairment of GLSR and 
GLSRe had superior diagnostic accuracy than the quantitative assessment of WMA 
in the detection of prior MI.  These results demonstrate that prior MI may be 
detected when GLS is impaired when LVEF is preserved, although its ability to 
detect prior MI in this context is moderate.   
Impairment of longitudinal measures of strain in prior MI may relate to myocardial 
fibre arrangement within the left ventricle.  Subendocardial myofibres contribute 
predominantly to contraction in the longitudinal plane with subepicardial fibres 
providing a lesser contribution.  Conversely, both circumferential and radial motion 
of the myocardium are generated by fibres predominantly located in the 
midwall(200).  Longitudinal function is particularly vulnerable to any disease 
process affecting the subendocardium.  It is therefore possible that in limited 
subendocardial MI, longitudinal myocardial deformation is reduced whereas radial 
function, which results from contraction of LV midwall fibres, may be relatively 
preserved.  Given that LVEF and systolic wall thickening are predominantly 
measures of radial contraction, this would explain the findings in this study that 
minimum SWT, presence of WMA and LVEF were all poor predictors of prior MI in 
patients with preserved LV function.  Delgado et al. demonstrated that although 
GLS was reduced in patients with HF-REF due to chronic ischaemic heart disease, 
the relationship between LVEF and GLS was only weakly linear (r=0.62, p= 
<0.001)(204) which would again potentially support the concept of impaired GLS 
being largely attributable to loss of subendocardial myocardial fibre contraction.  
There was no significant difference in the proportion of patients with WMA (>30% 
minimum SWT in any LV segments) between the prior MI and control groups.  Our 
finding of WMA in asymptomatic controls was not unexpected and has previously 
been reported elsewhere in the literature(205, 209).   
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The importance of LVEF and regional LV systolic function as indicators of prior MI 
is stressed in international guidelines(95).  Our results demonstrate the potential 
additive value of longitudinal strain parameters and in particular GLS in looking 
beyond traditional means of assessing LV systolic function in the detection of prior 
MI. 
Of the longitudinal strain parameters assessed, GLS was moderately useful in 
terms of specificity and sensitivity with a cut-off value of >-18% giving a sensitivity 
of 60% and specificity of 72.5% and was the most useful of the 3 strain values 
assessed.  These findings broadly correlate with those of Nucifora et al. who 
demonstrated a correlation between reduced GLS measured by echocardiography 
and the presence of significant coronary artery disease on CT coronary 
angiography in patients with symptoms suggestive of stable angina with normal 
LVEF(210).  In that study, the authors proposed a cut off value ≥-17.4% predicting 
significant coronary artery disease with a sensitivity of 83% and specificity of 77%.  
It is unclear why our own values for the sensitivity and specificity of GLS in 
identifying prior MI were lower, though one reason could be that ischaemia has a 
more profound effect on GLS than infarction, possibly due to the influence of LV 
remodelling in the context of chronic infarction. 
GLS has good inter and intra-observer variability when measured by CMR feature 
tracking as demonstrated in both this and another study(211).  Similar values have 
also been demonstrated using echocardiography(212).  The findings of this study 
adds to the growing evidence base supporting the use of GLS in clinical practice.  It 
has shown potential in terms of prognostication and has been demonstrated to be 
superior to LVEF in predicting morbidity and mortality in patients with IHD (213).  
Additionally, it shows promise as a potential screening tool for silent MI(214).   
Several studies have demonstrated impairment of GLS, predominantly by speckle 
tracking echocardiography, in a range of disease states including diabetes(215), 
heart failure with preserved ejection fraction (HFPEF)(216) and aortic 
stenosis(217).  In these studies, impairment of longitudinal function was attributed 
to a direct cardiomyopathic process.   However, LGE imaging was not performed in 
these patients and it is therefore possible that impairment of GLS may have related 
to unrecognised MI.  Thus, future studies of the prognostic importance of GLS 
should include LGE imaging to exclude MI as the mechanism of impairment of 
longitudinal function.   
Our findings support the potential utility of GLS as a screening tool for identifying 
prior MI in patients with preserved LV ejection fraction, although when used alone, 
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its ability to correctly identify prior MI in this context is only moderate.  Further 
prospective studies are needed to identify whether combining it with other imaging 
and/or clinical parameters lead to improvement in its specificity and sensitivity.  As 
GLS has been shown to be impaired independently of LVEF in aortic stenosis(217), 
hypertrophic cardiomyopathy(218) and heart failure with preserved ejection fraction 
(HFPEF) (216), it must be interpreted with caution where these conditions are 
present or are suspected. 
5.4.1. Limitations of the study 
The values for the strain parameters measured in this study were calculated using 
feature tracking post-processing software.  This remains a research application and 
currently lacks the clinical validation to enable its adoption into routine clinical 
practice.  Nevertheless, both GLS and GLSR can be readily measured using 
modern echocardiographic speckle tracking (22) which have been validated against 
CMR strain measurements(219) . 
CMR tagging has traditionally been considered the reference standard technique 
for calculation of strain values and was not used in this study.  We have elected to 
use feature tracking preferentially for this study because  tagging techniques suffer 
from both lower temporal resolution and fading of the tag overlay as the cardiac 
cycle progresses(211).  Furthermore agreement between feature tracking and CMR 
tagging is excellent(220) and can be easily performed without the need for 
acquisition of additional sequences.    
We have not carried out invasive assessment of coronary anatomy in all patients 
and it is possible that undiagnosed ischaemia may have contributed to impairment 
of longitudinal strain parameters. However, performing coronary angiography on 
patients in whom it is not clinically indicated would not be ethically appropriate. 
Finally, there were higher rates of CV risk factors in our prior MI population compared 
with healthy volunteers, thus it is unclear as to their relative contribution (if any) to 
the observed decrease in GLS seen in prior MI patients.  Nevertheless, in our 
multivariable analysis, only prior MI was an independent predictor of change in GLS 
and CV risk factors including hypertension, smoking, hypercholesterolemia and 
diabetes were not.  These CV risk factors were all potential confounding factors in 
the observation of lower GLS in the prior MI patients, although no studies to date 
have assessed their individual relative impact on GLS.  A future study may seek to 
address this by including additional control groups with no prior MI including 
hypertensive patients, diabetic patients and active smokers in addition to healthy 
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controls.  Pre-test probability of prior MI was not calculated in this study due to its 
retrospective selection of patients, however, this could also be performed in a future 
study, to assess whether longitudinal strain parameters provide incremental benefit 
above the use of standard clinical and non-invasive imaging tests.   
5.5. Conclusions 
The strain parameters GLS, GLSR and GLSRe are reduced in patients with prior MI 
in the context of normal LVEF.  A normal LVEF and lack of WMA is insufficient to 
exclude prior MI.  Prior MI may be suspected when impaired GLS, GLSR or GLSRe 
are detected by non-invasive imaging. 
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6. Assessment of Large Artery Involvement in Rheumatoid 
Arthritis Over Time: Prior to Diagnosis, at Diagnosis and 
in Established Disease 
6.1. Background 
Rheumatoid Arthritis (RA) is associated with an increase in cardiovascular mortality, 
approximately twice that of the general population(117).  Traditional risk factors 
alone are insufficient to explain this increase and inflammation is thought to be a 
major contributory factor.  Inflammation is thought to affect the vascular system of 
patients with RA through progressive endothelial dysfunction, arterial hardening 
(arteriosclerosis) and, eventually, largely irreversible atherosclerotic plaque 
formation in larger arteries(147).   
Demonstrating the time in the disease course of RA at which endothelial 
dysfunction first becomes evident may improve long-term CV outcomes in RA 
through earlier initiation of disease-modifying medication. Furthermore, greater 
understanding of how measures of arterial performance relate to CV outcomes may 
improve CV risk assessment in RA patients(125).  
Aortic stiffness can be assessed using non-invasive imaging as an indicator of 
function of the larger arteries and is a useful surrogate marker of increased risk of 
CV events(221).  Aortic stiffness is defined as resistance to deformation 
(lengthening or shortening) of the aortic wall(222).  The thoracic aorta, aside from 
its role as a conduit vessel, serves to dampen the high systemic pressures 
generated by the left ventricle in systole, protecting distal vascular beds of organs 
including the kidneys and brain(223).  This elastic recoil of the aorta diminishes 
naturally with ageing, resulting in damage to distal vascular beds and raised 
systemic blood pressure.  RA is thought to accelerate this process of vascular 
ageing and dysfunction.  Aortic stiffness has been reported to be increased in newly 
diagnosed(224) as well as established disease(225), but may begin even before a 
formal diagnosis of RA.  A ‘systemic autoimmune phase’ lasting months or even 
years is recognised, where the patient is largely asymptomatic, yet anti-cyclic-
citrullinated peptide (ACPA), a highly specific serological marker for RA, is 
raised(226).  Progression of such ‘at risk’ individuals can be predicted with the use 
of risk scoring models incorporating radiological parameters(227).  Measurement of 
radial and circumferential strain has been validated using speckle tracking 
echocardiography(191), showing promise in demonstrating the presence or 
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absence of atherosclerotic disease(228).  The presence of carotid plaque using 
ultrasound is a well-established marker of increased CVD risk in RA(229).  It is 
therefore likely that patients with plaque disease are furthest along the continuum of 
endothelial dysfunction, arteriosclerosis and eventual atherosclerosis.  For this 
reason, identifying a non-invasive imaging technique able to detect atherosclerotic 
plaque either directly or indirectly may strengthen its utility in CVD risk estimation.  
Circumferential carotid strain has been shown to be superior to carotid intima media 
thickness in predicting the presence and severity of coronary artery disease(194).  
Furthermore, carotid circumferential strain has also been shown to have a 
significant negative correlation with coronary calcium score (r= -0.4, p <0.01) which 
was not apparent with conventional measures of arterial performance(195).     
Aortic distensibility is a more established technique recognised as a surrogate 
marker of increased CV mortality with evidence of abnormalities in treatment-naïve, 
early RA(230) and established RA(231).  Limitations of assessing distensibility 
include its significant correlation with age and systolic BP(231).   
6.1.1. Hypothesis and Aims 
We hypothesised the following: 
1) Both aortic distensibility and aortic strain would be lower at all time points of 
RA (prior to diagnosis, at diagnosis and in established disease). 
2) Aortic circumferential strain would more accurately differentiate patients with 
established disease with and without CMR evidence of carotid plaque 
disease than aortic distensibility.  
The aim of this study was twofold: 
1) To assess the ability of an existing, established measure of aortic stiffness 
(aortic distensibility) and the novel measures of aortic stiffness (aortic radial 
and circumferential strain) to detect subclinical aortic stiffness in individuals 
at risk of RA as well as patients with newly diagnosed RA versus healthy 
controls. 
2) To assess the ability of an existing, established measure of aortic stiffness 
(aortic distensibility) and the novel measures of aortic stiffness (aortic radial 
and circumferential strain) to correctly identify atherosclerotic carotid plaque 
disease in a group of patients with established RA. 
 
- 76 - 
 
6.2. Methods 
The patient population for Chapter 6 “Assessment of Large Artery Involvement in 
Rheumatoid Arthritis Over Time: Prior to Diagnosis, at Diagnosis and in Established 
Disease” included healthy controls (n=30) and 3 RA populations (individuals at risk 
of RA (n=18), newly diagnosed, treatment naïve RA patients (n=83) and RA 
patients with established disease (n=40).  
At risk’ RA individuals were recruited between January 2016 and September 2016.  
This population included 18 consecutive patients with symptoms of arthralgia and 
detectable ACPA under active monitoring for the development of RA.  These 
patients were recruited from the outpatient clinic service at a tertiary centre (Chapel 
Allerton Hospital, UK) and underwent CMR at 3.0T (Philips, Achieva, Best, The 
Netherlands).  All patients had no history of previous CV disease (cardiac, 
peripheral or cerebral).  Positive ACPA was considered to be a serum level 
≥2.99U/ml (anti-CCP2; immunocap assay, Phadia, Uppsala, Sweden) at the time of 
recruitment.  Arthralgia was defined as pain in any joint, without clinical evidence of 
synovitis.  All participants were screened for CV risk factors by completion of a 
health questionnaire and from medical records.   
Newly diagnosed, treatment naïve RA patients were recruited between February 
2012 and November 2015.  This population consisted of 82 consecutive patients 
fulfilling the 2010 American College of Rheumatology/European League Against 
Rheumatism diagnostic criteria for RA who were recruited from the outpatient clinic 
service at a tertiary centre (Chapel Allerton Hospital, UK) as part of the CADERA 
study (Coronary Artery Disease in Early Rheumatoid Arthritis).  These patients were 
already recruited into the Very Early versus Delayed Etanercept in Rheumatoid 
Arthritis randomised drug trial (VEDERA).  All patients had a recent diagnosis of RA 
(less than 1 year), displayed signs of active disease (clinical or imaging evidence of 
synovitis and Disease Activity Score in 28 joints with Erythrocyte Sedimentation 
Rate (DAS28-ESR) ≥3.2 and had not previously received any DMARD therapy.  
Patients had no previous history of CV disease.  As part of the VEDERA trial 
patients were randomised to either the tumour necrosis factor inhibitor (TNFi) 
Etanercept combined with Methotrexate as first line therapy, or optimal standard 
therapy including Methotrexate as first line therapy, only escalating to Etanercept in 
combination with Methotrexate if a patient failed to achieve clinical remission from 
RA 24 weeks or more after enrolment(166).   
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Following a baseline scan immediately after recruitment, 71 of these patients 
underwent a repeat year one scan between 51 and 53 weeks after their baseline 
scan. 
Established RA patients were recruited between February 2011 and August 2014.  
This population consisted of 40 consecutively recruited patients fulfilling the 1980 
American College of Rheumatology diagnostic criteria for RA were recruited from 
the outpatient clinic service at a tertiary centre (Chapel Allerton Hospital, UK) and 
scanned at 3.0T (Philips, Achieva, Best, The Netherlands) as part of the IACON 
(Inflammatory Arthritis disease CONtinuum) study.  At the same time as the CMR 
scan, these patients also underwent a series of Time of Flight, proton-density, T1 
and T2-weighted acquisitions of both carotid arteries, deemed to be of diagnostic 
quality for both the right and left carotid arteries.  All patients had been diagnosed 
with RA for > 5 years.  Patients had no previous history of CV disease (cardiac, 
peripheral or cerebral) or diabetes.   
Healthy volunteers for this study were recruited between September 2014 and 
March 2015 and scanned at 3.0T at Leeds General Infirmary, UK.  The population 
included 30 volunteers with no prior history of RA or prior CV disease (cardiac, 
peripheral or cerebral) who were consecutively recruited on a volunteer basis to 
undergo CMR examination.  These were matched in age and gender to the 
treatment naïve, newly diagnosed RA patients. 
Exclusion criteria in all groups included known CVD (including ischaemic heart 
disease heart failure or cardiac arrhythmia), renal failure (estimated glomerular 
filtration rate <30ml/min-1) and inability to undergo CMR due to obesity.   
Cardiovascular risk factors such as hypertension, diabetes, hypercholesterolaemia 
and smoking status were assessed by history and medical records.  Hypertension 
was defined as blood pressure >140/90mmHg or the use of anti-hypertensive 
medications.  Diabetes was defined as fasting glucose ≥7mmol/L-1, HbA1C 
≥48mmol/mol, or the use of oral anti-hyperglycaemia medication or subcutaneous 
insulin.  Hypercholesterolaemia was defined as total cholesterol <5mmol/L-1 or the 
use of statin medication.   
The sample sizes were based on the maximum available number of patients within 
each cohort during the recruitment periods, accepting that the sample size for 
individuals at risk of RA (n=18) is relatively low owing to difficulty in recruitment of 
this cohort.     
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6.2.1. CMR protocol 
All patients underwent CMR at 3.0T (Philips Achieva).  Images were acquired with 
breath holding on end-expiration prior to contrast administration and prospectively 
gated using a 3-lead vector ECG.  The CMR protocol for all patients included a cine 
LV short axis covering the long axis of the LV in its entirety, with one slice acquired 
per breath hold in end-expiration, parallel to the mitral valve annulus (bSSFP, 
multiphase, 10-12 contiguous slices, spatial resolution 2.0 x 1.63 x 10mm, 30 
cardiac phases).  Additionally, 50-phase cine acquisitions of the ascending and 
descending aorta were acquired as described in the methods chapter. 
   
Patients in the established RA patient cohort also underwent a series of non-
contrast, non-breath held MR images at 3.0T (Philips Achieva, Philips, Best, The 
Netherlands) which were acquired using a 10cm phased array coil (Philips dStream 
Flex, Best, The Netherlands).  Survey images were used to locate the point of 
bifurcation of the common carotid into the internal and external carotid artery.  
Perpendicular, axial slices were then planned form the survey images.  Time of 
flight (ToF), proton density-weighted (PD), T1 and T2-weighted slices were then 
acquired (10 slices in total; 5 above and 5 below the carotid bifurcation).  Spatial 
resolution for ToF acquisitions was 0.89 x 0.89 x 3mm, PD 0.7 x 0.7 x 2mm, T1 0.7 
x 0.7 x 2mm and T2 0.7 x 0.7 x 2mm.  
 
6.2.2. CMR analysis 
All post processing analysis of CMR scans was performed using the same software 
(CVI 42, Circle Cardiovascular Imaging Calgary, Canada).  Analysis of scans was 
performed by a single assessor with 2 years’ experience in CMR reporting blinded 
to all patient details.  Left ventricular contours were drawn manually at both end 
diastole and end systole on the LV short axis SSFP cine stack.  LV papillary 
muscles were considered part of the LV cavity.  Aortic distensibility was calculated 
according to previously described methods(181).  Radial and circumferential aortic 
strain were calculated using post-processing CMR-FT analysis as described in 
detail within chapter 4.  
 Carotid T1/T2/TOF and PD acquisitions were visually assessed for the presence or 
absence of carotid atherosclerotic plaque, graded according to previously described 
methods(232).  Patients were only included in the analysis if image quality of both 
carotid arteries was of diagnostic quality.  Carotid atherosclerotic plaque was 
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considered present when either artery showed either diffuse intimal thickening, 
evidence of small eccentric plaque within the vessel lumen or more obvious larger 
eccentric plaque with clear narrowing of the vessel lumen (see figure 6-1). 
 
 
 
 
 
Figure 6-1 Example of CMR carotid imaging 
 
Panel A shows PD acquisition of right carotid artery in patient with no evidence of 
atherosclerotic plaque.  Panel B shows PD acquisition of left carotid artery with 
evidence of eccentric atherosclerotic plaque formation (see red asterisk). 
 
 
 
6.2.3. Statistical analysis 
Normality of data was tested using a Shapiro-Wilk test.  Mean values ± SD are 
reported.  Unpaired Student t-test and Mann-Whitney U test were used as 
appropriate to compare continuous variables.  
 Cut-off values to identify presence of carotid atherosclerotic plaque were derived 
from ROC curve analysis using Youden index giving maximum sensitivity and 
specificity.  AUCs were compared by using validated methods described by DeLong 
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et al(208).  All tests were two-sided and p<0.05 was considered statistically 
significant. 
6.2.4. Ethical approval: 
The study was conducted according to the declaration of Helsinki.  All patients gave 
their written, informed consent to take part in the study.  Patients were recruited 
from a number of different studies covered by the following National Research 
Ethics Committee approvals 09/1-11307/98, 10/H1307/138 & 12/YH/0551. 
6.3. Results 
6.3.1. Feasibility of vascular performance measurements 
Analysis of descending aortic radial and circumferential strain was possible in 
162/169 (96%) of all patients included in the study and was not possible in 1/18 
(3%) at risk of RA, 6/81 (7%) newly diagnosed RA patients all due to degradation of 
image quality due to flow artefact.  Assessment of aortic distensibility was possible 
in all 169 patients.   
6.3.2. Patient characteristics (healthy controls, at risk RA 
and newly diagnosed RA) 
Patient characteristics of healthy controls, at risk RA and newly diagnosed patients 
are shown in table 6-1 on following page.  Healthy controls were well matched with 
at risk RA and  newly diagnosed RA patients for age and gender.  There were also 
no statistically significant differences between these groups for systolic or diastolic 
blood pressure (BP), hypertension and hypercholesterolaemia and proportion of 
active smokers.  There were significant differences between groups for body mass 
index (BMI), diabetes, proportion of ex-smokers and mean pack years of smoking. 
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Table 6-1 Patient demographics (healthy controls, at risk RA and newly 
diagnosed RA) 
Characteristic* Healthy 
controls 
(n=30) 
At risk RA 
(n=18) 
Newly 
diagnosed RA 
(n=81) 
p value (between 
groups) 
Age (yrs) 49±16 53±12 49±13 0.52 
Females (%) 19/30 (63%) 14/18 
(78%) 
55/81 (68%) 0.59 
BMI 25.3±4.6 28.7±5.4 25.7±4.6 0.03 
Systolic BP  119±12 122±16 121±15 0.70 
Diastolic BP 65±13 65±11 70±11 0.05 
Hypertension (%) 0/30 1/18 (6%) 6/81 (7%) 0.32 
Hypercholesterolaemia(%) 0/30 0/18  2/81 (2%) 0.55 
Diabetes (%) 0/30 2/18 (11%) 0/81 0.002 
Active smoker (%) 3/30 (10%) 2/18 (11%) 17/81 (21%) 0.31 
Ex-smoker (%) 5/30 (17%) 10/18 
(56%) 
25/81 (31%) 0.02 
Pack years  1±4 10±14 6.8±12 0.01 
CRP ≥5 (%) - 5/18 (28%) 50/81 (62%) - 
ESR - 12.9±13.3 36.8±27.2 - 
RF positive (%) - 8/18 (44%) 60/81 (74%) - 
CCP positive (%) - 18/18 
(100%) 
68/81 (84%) - 
DAS28-ESR - - 5.6±1.1 - 
Predicted risk of RA (%) - 49±17 - - 
 
*Mean ± SD unless stated otherwise 
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6.3.3. Patient demographics (established RA) 
CMR evidence of carotid atherosclerotic plaque disease was evident in 22/40 (55%) 
patients with established RA.  There were no statistically significant differences in 
demographic data between patients with and without carotid plaque (table 6-2), 
although there was a trend towards higher BMI, active smoker status and higher 
systolic BP in those with plaque versus those without. 
 
Table 6-2 Patient demographic data (established RA) 
Characteristic* Established 
RA (n=40) 
Carotid  
plaque 
present (n= 
22) 
Carotid 
plaque 
absent 
(n=18) 
p value (carotid 
plaque present 
vs. absent) 
Age (yrs) 58.6±8.7 59.4±8.9 57.7±8.6 0.54 
Females (%) 30/42 
(71%) 
73% 70% 0.97 
BMI 25.4±3.0 26.1±3.1 24.6±2.7 0.10 
Systolic BP 134±19 137±23 131±14 0.36 
Diastolic BP 80±11 80±14 81±7 0.64 
Hypertension (%) 13/42 
(31%) 
36% 28% 0.58 
Hypercholesterolaemia (%) 11/42 
(26%) 
23% 33% 0.47 
Diabetes (%) 0/42 0% 0% - 
Active smoker (%) 5/42 (12%) 18% 6% 0.24 
Disease durations (yrs) - 17±11 19±9 0.45 
CRP ≥5 (%) 16/42 
(38%) 
36% 39% 0.87 
ESR 24±27 22±25 28±31 0.53 
RF positive (%) 29/42 
(69%) 
68% 67% 0.92 
CCP value 151±134 122±138 181±124 0.21 
DAS28-ESR 3.2±1.6 3.3±1.7 3.0±1.6 0.81 
 
*Mean ± SD unless stated otherwise 
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6.3.4. CMR findings in at risk RA and newly diagnosed RA 
patients versus healthy controls 
CMR results are shown in table 6-3.  There were no statistically significant 
differences between groups for left ventricular ejection fraction (LVEF), left 
ventricular end diastolic volume (LVEDV), LVEDV indexed to body surface area 
(BSA), right ventricular ejection fraction (RVEF) or left ventricular (LV) mass.  LV 
mass indexed to BSA was  significantly reduced between groups (p=0.03). 
 
Table 6-3 CMR findings (healthy controls, at risk RA and newly diagnosed 
RA patients) 
Variable* Healthy 
controls (n=30) 
At risk RA 
(n=18) 
Newly diagnosed 
RA (n=81) 
p value 
(between 
groups) 
LVEF (%) 62±5 62±4 61±6 0.42 
LVEDV (ml) 146±25 155±23 148±33 0.61 
LVEDVi (ml/m2) 78±10 83±12 80±13 0.47 
RVEF (%) 54±7 55±6 54±5 0.76 
LV Mass (g) 91±18 87±24 81±23 0.10 
LVMi (g/m2) 49±8 46±10 44±9 0.03 
Distensibility (10-3mmHg-1) 4.9±2.1 3.6±1.4 3.4±1.5 <0.001 
Radial strain (%) -8.1±3.6 -6.4±2.9 -6.4±2.8 0.04 
Circumferential strain (%) 10.3±5.4 7.7±3.9 7.2±4.8 0.01 
Ratio of radial to 
circumferential strain 
-0.81±0.07 -0.86±0.05 -0.84±0.19 0.61 
 
*Mean ± SD unless stated otherwise 
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Mean (SD) aortic distensibility (figure 6-2 on following page) was 4.9±2.1 in healthy 
controls, 3.6±1.4 in at risk RA individuals and  3.4±1.5 x 10-3mmHg-1 in newly 
diagnosed RA.  Aortic distensibility in at risk RA individuals (p= 0.02) as well as 
early RA patients (p=<0.001) was significantly lower than in healthy controls, with 
no significant difference between at risk RA individuals and early RA patients 
(p=0.54).   
Radial strain (figure 6-2 on following page) was -8.1±3.6 in healthy controls, -
6.4±2.9 in at risk RA individuals and -6.4±2.9% in early RA patients.  Radial strain 
was significantly lower in early RA versus healthy controls (p= 0.01) with no 
significant difference between at risk RA individuals and early RA patients (p=0.91). 
Circumferential strain (figure 6-2 on following page) was 10.3±5.4 in healthy 
controls, 7.7±3.9 in at risk RA individuals and 7.2±4.8% in early RA.  
Circumferential strain was significantly reduced in early RA versus healthy controls 
(p=0.004) with no significant difference between at risk RA individuals and early RA 
patients (p=0.75).  
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Figure 6-2 Measures of aortic stiffness in controls, at risk RA and early RA 
Panel A: aortic distensibility.  Panel B: radial strain.  Panel C: circumferential strain.  p values shown in legend below box and whisker charts. 
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6.3.5. CMR findings in Established RA 
CMR findings in established RA are summarised in table 6-4.  Circumferential strain 
(5.7±3.0 vs. 6.7±2.6% p=0.29), radial strain (-4.9±2.4 vs. -5.7±2.0%,p= 0.27)  and 
ratio of radial to circumferential strain (-0.89±0.05 vs. -0.87±0.04, p=0.22) were all 
lower in patients with carotid plaque versus those without, however, this was not 
statistically significant (table 6-4).  Aortic distensibility was similar in patients with 
and without carotid plaque (2.6±1.4 vs. 2.7±1.2 x 10-3mmHg-1, p=0.89).  
The ability of aortic distensibility, radial and circumferential strain and ratio of radial 
to circumferential strain to correctly identify the presence of atherosclerotic carotid 
plaque disease was assessed with ROC analysis (table 6-5 on following page).  All 
strain parameters were mildly effective in correctly identifying plaque, however, no 
single variable or a combination of 3 strain variables reached statistical significance. 
Table 6-4 CMR Findings in Established RA 
 
*Mean ± SD unless stated otherwise 
 
 
 
 
Variable* All established 
RA patients 
(n=40) 
Carotid  plaque 
present (n= 22) 
Carotid plaque 
absent (n=18) 
p value 
LVEF (%) 60±5 - - - 
LVEDV (ml) 143±30 - - - 
LVEDVi (ml/m2) 80±15 - - - 
RVEF (%) 58±6 - - - 
LV Mass (g) 64±22 - - - 
LVMi (g/m2) 36±12 - - - 
Distensibility 2.6±1.3 2.6±1.4 2.7±1.2 0.89 
Radial strain -5.1±2.4 -4.9±2.4 -5.7±2.0 0.27 
Circumferential strain 6.1±2.9 5.7±3.0 6.7±2.6 0.29 
Ratio of radial to 
circumferential strain 
-0.88±0.04 -0.89±0.05 -0.87±0.04 0.22 
- 87 - 
 
Table 6-5 Accuracy of CMR measures of vascular performance in 
identifying presence of carotid atherosclerotic plaque 
 
 
 
6.4. Discussion 
In this study, we assessed the use of a novel, CMR-FT derived measure of aortic 
radial and circumferential strain, as well as aortic distensibility in healthy controls, 
individuals at risk of RA, newly diagnosed, treatment naive RA and established RA 
patients with and without carotid atherosclerotic plaque.   
We have demonstrated 3 key findings.  Firstly, measurement of aortic radial and 
circumferential strain by CMR-FT is both technically feasible and is able to detect 
abnormalities in arterial stiffness at different time points in the RA disease 
continuum.  Secondly, perhaps most significantly, we have demonstrated increased 
arterial stiffness in individuals at risk of developing RA compared with controls, 
which is similar in magnitude to that seen in newly diagnosed, treatment naïve RA.  
Thirdly, we have shown a weak association between reduced aortic strain values by 
CMR and the presence of atherosclerotic carotid plaque. 
Measurement of aortic radial and circumferential strain by CMR-FT was technically 
feasible in a high proportion of patients; 162/169 (96%) of all patients included in 
this study.  In the small number of patients where this was not possible, this was 
due to flow artefact on the cine acquisition.  This meant that the endothelial border 
of the aorta was obscured throughout the systolic phase and the computer software 
tracked image artefact in preference, leading to abnormal appearances of the strain 
curve and erroneously high strain values.  Flow artefact is relatively common on 
CMR cine acquisitions where high velocity blood flow occurs within the imaging 
slice and is more prevalent at 3.0T(19).  Image degradation from flow artefact can 
Vascular performance measure AUC median (95% C.I.) p value 
Distensibility 0.530 (0.349-0.712) 0.74 
Radial strain 0.601 (0.288-0.778) 0.28 
Circumferential strain 0.604 (0.427-0.780) 0.27 
Ratio of radial to circumferential strain 0.601 (0.423-0.779) 0.28 
Combination of 3 strain variables 0.611 (0.434-0.788) 0.23 
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almost always be overcome, by altering the phase-encoding direction of the 
acquisition and by carefully ‘shimming’ over the area of interest to ensure 
homogeneity of the magnetic field.   
To our knowledge this is the first study showing subclinical aortic stiffness amongst 
individuals with raised ACPA  and non-specific musculoskeletal symptoms deemed 
‘at risk’ of developing RA.  Although our sample size was small, aortic distensibility 
was significantly reduced versus healthy controls and close to the values seen in 
newly diagnosed, treatment naïve RA.  This was somewhat surprising given mean 
predicted absolute risk of at risk patients developing RA was 46% and may imply a 
role of ACPA-mediated arteriosclerosis predating synovitis and a clinical diagnosis 
of RA.  One previous study has shown both the presence of ACPAs within 
atherosclerotic plaque, as well as an association between some ACPAs and 
computerised tomography detected atherosclerotic plaque burden in female 
patients with RA(233).   
The apparent aortic stiffness in at risk RA individuals we have demonstrated may 
represent the earliest indication of a process culminating in accelerated 
atherosclerotic plaque formation, though our findings need to be confirmed in larger 
and, ideally, longitudinal studies to assess changes in aortic stiffness of time in 
these individuals.  Specifically, such studies should include appropriate negative 
controls (i.e. proven ACPA negative controls as well as ACPA positive but no 
musculoskeletal symptom controls) and evaluate and compare CV changes in 
patients ultimately progressing (or not progressing) to a clinical diagnosis of RA. 
The finding of a high proportion of patients with evidence of atherosclerotic plaque 
formation in the cohort of established RA patients (55%) was in line with previous 
ultrasound studies (234, 235).  Although CMR-FT measures of radial and 
circumferential strain as well as the ratio of these two values showed a weak 
predictive accuracy in assessing the presence of atherosclerotic carotid plaque, this 
did not reach statistical significance.  Furthermore, aortic distensibility showed an 
even lower predictive accuracy in assessing the presence of atherosclerotic carotid 
plaque.  A limited ability of both aortic strain and distensibility in distinguishing 
between patients with and without carotid plaque may reflect that aortic stiffness 
increases and plateaus due to endothelial dysfunction and arteriosclerosis and 
subsequently does not increase further once atherosclerotic plaque forms.  
Translating this to its potential utility in CVD risk assessment in RA, this may mean 
that measures of aortic stiffness are most useful in identifying patients at 
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heightened CVD risk earlier in the disease course, but may not separate out those 
at the very highest risk much later in the disease.   
6.4.1. Study limitations 
Our sample size of individuals at risk of RA was low (n=18).  As such, the study 
should really be considered as a pilot study suggesting evidence of increased aortic 
stiffness prior to a clinical diagnosis of rheumatoid arthritis, but not definitively 
proving this is the case.  The same cohort included two patients with type 2 
diabetes which may have been a confounding factor, although the measures of 
aortic stiffness aligned numerically with those of individuals without diabetes and 
the confidence intervals of all 3 measures of aortic stiffness were narrow in this 
cohort. There were high rates of smoking in both the at risk RA and early RA 
groups in comparison to the healthy control group.  Smoking itself may be 
associated with raised ACPA(236), thus high rates of smoking in at risk RA 
individuals is unsurprising.  The extent, if any, to which smoking in at risk RA 
individuals affected measures of aortic stiffness in this study is unclear, however, 
previous studies have not demonstrated any effect of chronic smoking on aortic 
stiffness(237).   
  
Although the ability of descending aortic circumferential strains to correctly predict 
the presence of carotid atherosclerotic plaque was better than that of aortic 
distensibility (AUC 0.604  vs. 0.530 respectively) this predictive accuracy was weak 
and not statistically significant.  Ideally atherosclerotic plaque imaging and strain 
values would also have been assessed in the same large artery (carotid or 
descending aorta), cine imaging of the carotid artery was not available in this study.  
Nevertheless our findings suggest that measures of aortic strain (as well as aortic 
distensibility) by CMR feature tracking is limited in its ability to correctly identify 
carotid artery atherosclerotic plaque.  
6.5. Conclusion 
CMR assessment of aortic strain is feasible and demonstrates reduced arterial 
stiffness in new onset RA.  Aortic stiffness appears to be increased in individuals at 
risk of developing RA with symptoms of arthralgia and detectable ACPA, though 
larger scale studies are required to confirm this finding.  The presence of 
atherosclerotic plaque in patients with established RA is a common finding 
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associated with current smoking status.   The ability of both CMR-FT aortic strain 
and aortic distensibility to identify patients with carotid plaque is limited.  
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7. CMR Assessment of Newly Diagnosed Treatment Naïve 
RA Patients at Baseline and 1 Year After Randomisation to 
Either Etanercept & Methotrexate or Standard Therapy  
7.1. Background 
The pathogenesis of CVD in RA is incompletely understood and the small number 
of previous studies evaluating this have focussed almost exclusively on 
heterogeneous patient populations with established disease.  It is therefore unclear 
as to the nature and extent of CVD in RA at the time of diagnosis, prior to treatment 
initiation.  Furthermore, the impact of both conventional synthetic DMARD therapy 
(csDMARD) and modern biological disease modifying anti-rheumatic drugs 
(bDMARD) on the structure and function of the CV system in RA remains unknown.  
Evidence from the literature supports treatment as early as possible in the course of 
RA.  Although the rate of CV events is low in the early stages of RA, delayed 
diagnosis is associated with higher rates of CV events, with hypertension being the 
strongest independent predictor of CV events(238).  
 Current European League Against Rheumatism guidelines recommend that 
patients with newly diagnosed RA are commenced on a csDMARD therapy in 
combination with glucocorticoids(239).  bDMARD therapy, including TNFi therapy, 
is recommended only if csDMARDs (usually at least 2 are tried, including 
methotrexate, MTX) fail to confer adequate disease control, with escalation to 
bDMARD particularly advised in poorer prognostic groups(239).  Strategy studies 
comparing first-line csDMARD in a treat to target approach versus TNFi show 
variable results, demonstrating equivalence or superiority of first-line TNFi. 
Improvements in radiographic evidence of joint disease and higher rates of drug 
free remission have been demonstrated with bDMARD therapy as well as similar or 
slightly greater remission induction rates (240–242).   
In addition to the role of DMARD strategies in improving the traditional aspects of 
RA, there is significant focus on the extent to which effective RA disease control 
can also improve co-morbidity, especially CVD.  Long-term registry data have 
demonstrated a significant reduction in the incidence of acute myocardial infarction 
in patients receiving TNFi versus sDMARD therapy(243).  For this reason, such 
considerations are becoming increasingly relevant in determining optimal treatment 
strategies in RA.   
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Here we report the findings of CADERA study, to our knowledge the first study to 
assess the extent of subclinical CVD in treatment naïve, newly diagnosed patients 
with no known cardiovascular disease and establish the degree of improvement 
following initiation of RA.  This study was conducted as a bolt-on study to a phase 
IV, pragmatic, single-centre, open-label, randomised control trial, VEDERA. The 
purpose of CADERA was to assess CVD using multi-parametric CMR assessment 
in patients with new onset, treatment naïve RA before and 12 months after initiation 
of either (i) immediate TNFi (etanercept, ETN) and MTX or (ii) MTX +/- additional 
csDMARD in a treat to target approach with switch to delayed ETN and MTX in the 
event of failure to achieve clinical remission at 6 months.  
7.1.1. Hypothesis and aims 
We hypothesised that treatment with initial ETN-MTX would lead to improved aortic 
stiffness in comparison to standard RA treatment comparing aortic distensibility by 
CMR at baseline (pre treatment) and 1 year after commencement of treatment.  We 
also hypothesised that other markers of subclinical disease in RA would improve 
following initiation of treatment for RA. 
The aims were as follows:  
Primary objective 
 To establish whether (any) RA DMARD strategy is associated with 
improvement in AD over a 1 year period 
Secondary objectives 
To explore whether the following factors affect AD change over 1 year: 
 DAS28 control (DAS28 defined clinical response/non-response) 
 Therapeutic intervention (TNFi/MTX and conventional DMARD including MTX) 
Aortic distensibility was chosen as the primary outcome for the study due to its 
dynamic nature, high reproducibility and ability to predict major CV events 
independently of traditional clinical risk scoring models in patients with no known 
CVD(244).  The alternative methods for assessing vascular performance developed 
in Chapter 4 and tested on patient populations in Chapter 6 (aortic radial and 
circumferential strain) were not used on the basis they 1) offered no statistically 
significant benefit over AD in correctly identifying the presence of atherosclerotic 
plaque disease and 2) currently lack longitudinal prognostic outcome data to 
validate their utility as a biomarker for increased risk of CVD. 
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7.2. Methods 
The methods used in VEDERA(245) and CADERA(166) have been published 
previously.  Patients were recruited between February 2012 and November 2015 
from a single tertiary centre, early RA Rheumatology outpatient clinic (Chapel 
Allerton Hospital, Leeds, UK).   
The patients included in this chapter were the same treatment naïve, newly 
diagnosed RA patients included in chapter 6; baseline and year 1 scans were used 
for this chapter.  
Consecutive patients diagnosed with new onset RA according to ACR/EULAR 2010 
criteria(240) were invited to enrol into the VEDERA randomised control trial and 
parallel CADERA CVD sub-study.  Inclusion criteria included no previous use of 
DMARD therapy, symptom duration ≤ 1 year, DAS28-ESR ≥3.2 and at least one 
poor prognostic factor (positive anti-citrullinated protein antibody (ACPA) +/- 
abnormal power Doppler in any joint).  Exclusion criteria included prior DMARD 
therapy, contra-indications to TNFi therapy or patients considered clinically 
unsuitable for TNFi therapy by the treating physician.  Additional exclusion criteria 
for CADERA included renal failure (estimated glomerular filtration rate (e-GFR)  
<30ml/min/1.73m2), contra-indications to intravenous adenosine (asthma or high 
degree AV block), known allergy to Gadolinium-based contrast agent (GBCA), 
claustrophobia, weight ≥ 120kg and metallic implant/foreign body deemed unsafe to 
for CMR.  
All patients were randomised on a 1:1 basis either to immediate Etanercept in 
combination with Methotrexate (ETN-MTX) or Methotrexate with or without 
additional csDMARD with escalation to Etanercept in patients not achieving clinical 
remission at week 24 T2T (treatment to target) (MTX-T2T ± ETN-MTX).  Clinical 
remission was defined as DAS28-ESR ≥2.6(246).  Clinical response was imputed 
using baseline DAS28 score for patients whose responder status at 24 weeks was 
unknown. 
CMR scans were conducted at baseline (prior to the commencement of RA 
treatment) and 1 year after enrolment.  Scans were performed on the same 3.0T 
system (Philips Achieva, Best, The Netherlands).  The CMR protocol included left 
and right ventricular volumes, left ventricular mass, CMR-tagging, aortic 
distensibility, adenosine stress and rest first pass perfusion imaging using a dual 
bolus technique with intravenous infusion of 0.01 and 0.1mmol/kg Gadopentate 
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Dimeglumine (Magnevist, Bayer, Berlin, Germany),  T1 mapping pre and post 
GBCA and late Gadolinium enhancement (LGE) imaging.    
All post processing analysis of CMR scans was performed using the same software 
(CVI 42, Circle Cardiovascular Imaging Calgary, Canada).  Analysis of scans was 
performed by two assessors (GF,BE) both with 2 years’ experience in CMR 
reporting blinded to all patient details. LV contours were drawn manually at both 
end diastole and end systole on the LV short axis SSFP cine stack.  LV papillary 
muscles were considered part of the LV cavity.  Aortic distensibility was calculated 
according to previously described methods(181). 
Statistical analysis was performed using IBM SPSS® Statistics 22.0 (IBM Corp., 
Armonk, New York, USA) and R version 2.14.1 (The R Foundation for Statistical 
Computing, Vienna, Austria).   
The sample-size estimation for the primary endpoint aortic distensibility was based 
on previous work by Ikanomidis et al showing improved aortic distensibility in RA 
patients in response to interleukin-1 therapy(247).  We calculated that 33 patients in 
each treatment group would equate to an 80% power to detect a difference in aortic 
distensibility between the two treatment groups at a 5% significance level.   
Normality of data was tested using a Shapiro-Wilk test.  Mean values ± SD are 
reported where data are normally distributed and as median values with 
interquartile range where data were non-normally distributed.  The primary outcome 
aortic distensibility was analysed using an intention-to-treat (ITT) analysis with 
assistance from a biostatistician (EH).  The methodology for this ITT analysis is 
summarised in the appendix (page 158-159).  Distensibility values were natural log-
transformed prior to analysis.  Missing data were imputed using an imputation 
model including numerous clinical and demographic data, allowing adjusted 
analyses to be performed via multiple regression (see appendix).  Exploratory 
analyses were compared using paired t tests and Wilcoxon signed rank tests as 
appropriate.   
7.2.1. Ethical approval: 
The study was conducted according to the declaration of Helsinki with approval 
from the local ethics committee (National Research Ethics Committee reference: 
10/H1307/138).  All participants gave written informed consent to take part in the 
study. 
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7.3. Results: 
A total of 81 patients were enrolled into CADERA and underwent baseline CMR 
scan, with 71 undergoing a 1 year CMR scan (figure 7-1).  A total of 4 of the 
patients were withdrawn from the study; one due to treatment non-compliance and 
the other 3 all due to serious adverse events relating to treatment.  The reasons for 
the remaining 7 patients not undergoing a 1 year CMR scan included refusal or 
claustrophobia (6 patients) and 1 patient who moved away and was not able to 
attend a repeat scan. 
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Figure 7-1 Study recruitment flowchart 
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Median age of the 81 patients scanned at baseline was 51 years (IQR 39-61), 
26/81 (32%) were male and mean baseline DAS28-ESR score was 5.6±1.1.  All 
CMR studies were of diagnostic quality with interpretable data for all 81 baseline 
scans and 71 one year follow up scans.  Patient demographics at study baseline 
are summarised in table 7-1 for both the whole CADERA study population and 
within each treatment arm.  Baseline demographic data were similar across both 
treatment arms for all variables with the exception of median pack years of 
smoking.  
Table 7-1 Baseline demographic data 
Variable* All baseline 
CADERA 
(n=81) 
ETN-MTX 
group (n=40) 
MTX-T2T 
±ETN-MTX 
group (n=41) 
p value ETN-
MTX vs. 
MTX-T2T 
±ETN-MTX 
Male gender 26/81 (32%) 16/40 (40%) 10/41 (24%) 0.14 
Age (years) 51 (39-61) 51 (39-61) 54 (38-61) 0.45 
BMI (kg/m2) 25 (23-28) 25 (23-28) 25 (23-28) 0.84 
ESR 30 (18-49) 30 (18-49) 30 (20-50) 0.38 
CRP 8 (0-25) 8 (0-49) 8 (1-20) 0.90 
CCP positive 67/81 (83%) 32/40 (80%) 35/41 (85%) 0.53 
RF positive 57/81 (70%) 26/40 (65%) 31/41 (76%) 0.30 
Baseline DAS28 score 5.6±1.1 5.7±1.2 5.6±1.0 0.61 
6-month DAS28 score 3.3±1.5 3.1±1.6 3.5±1.4 0.34 
Hypertension 6/81 (7%) 1/40 (3%) 5/41 (12%) 0.10 
Hypercholesterolaemia 2/81 (3%) 0/40 2/41 (5%) 0.16 
Diabetes 0/81 0/40 0/41 - 
Family history IHD 7/81 (9%) 2/40 (5%) 5/41 (12%) 0.26 
Current smoker 17/81 (21%) 6/40 (15%) 11/41 (27%) 0.20 
Ex smoker 28/81 (35%) 12/40 (30%) 16/41 (39%) 0.40 
Pack years smoking 2 (0-11) 0 (0-6) 4 (0-20) 0.03 
*Mean ± SD or median (IQR) unless stated otherwise 
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7.3.1. Primary objective (aortic distensibility) 
At 1 year in the combined treatment groups (n=81) there was an increase in aortic 
distensibility of 19.6% (geometric mean ratio 1.196 CI 1.08, 1.324) which was highly 
statistically significant; p<0.001.  
An intention-to-treat analysis was performed to assess change in aortic distensibility 
between baseline and 1-year CMR which is displayed in table 7-2 and figure 7-2 on 
the following pages.   
 
Treatment groups were defined as follows: 
 
 Group 1: First line ETN-MTX 
 Group 2: First-line MTX-T2T ± ETN-MTX 
 
Treatment subgroups were defined as follows: 
 Group 1a: First line ETN-MTX responders (24-wk DAS28-ESR ≥2.6) 
 Group 1b: First line ETN-MTX non-responders (24-wk DAS-ESR <2.6) 
 Group 2a: First line MTX-T2T responders remaining on MTX-T2T                                                        
(24-wk DAS28-ESR ≥2.6)       
 Group 2b: First line MTX-T2T non-responders escalating to ETN-MTX 
(24-wk DAS-ESR <2.6)  
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Table 7-2 Differences between treatment groups and subgroups, either 
adjusted for 24-week DAS28-ESR or additionally adjusted for age/sex 
 
 
 
 
*Adjusted 1: Adjusted for 24-week DAS28-ESR 
*Adjusted 2: Adjusted for age and sex (±DAS28-ESR as appropriate) 
The results were unchanged when adjusted for baseline aortic distensibility 
 
 
 
 
 
Comparison Geometric 
mean 
(unadjusted) 
Ratio (95% CI), P value 
Unadjusted Adjusted 1 * Adjusted 2 ** 
Group 1  
(n=40)  
Group 2  
(n=41) 
 
3.77 3.40 0.90 (0.69, 
1.17), p=0.436 
n/a 0.89 (0.71, 
1.12), p=0.311 
Group 1a          
(n=16)  
Group 2a 
(n=19) 
 
3.31 2.91 0.88 (0.58, 
1.34), p=0.537 
n/a 0.82 (0.58, 
1.15), p=0.234 
Combined 
groups 1b + 2b 
(n=46) 
 
 Combined 
groups 1a + 2a  
(n=35)      
4.00 3.09 0.77 (0.59, 
1.00), p=0.050 
0.69 (0.48, 
0.98), p=0.040 
0.76 (0.55, 
1.05), p=0.095 
Group 2b 
(n=22) 
 
Group 2a 
(n=19) 
3.88 2.91 0.75 (0.51, 
1.10), p=0.138 
0.67 (0.40, 
1.10), p=0.106 
0.76 (0.48, 
1.21), p=0.239 
Combined 
Group 1 + 2b 
(all ETN-MTX 
patients) (n=62) 
 
Group 2a 
(n=19) 
3.81 2.91 0.76 (0.56, 
1.04), p=0.086 
0.76 (0.55, 
1.06), p=0.106 
0.78 (0.59, 
1.03), p=0.075 
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Figure 7-2 1 year aortic distensibility in responders and non-responders to 
first-line ETN and to standard therapy +/- delayed ETN 
Box and whisker plot of aortic distensibility across treatment groups.  The horizontal 
line within the box represents the median value, the bottom line of the box 
represents the 25th centile and the top of the box the 75th centile.  The narrower 
‘whiskers’ above and below the box represent the 95% confidence interval.   
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7.3.2. Secondary outcome measures 
A number of other exploratory CMR markers of subclinical CVD were assessed in 
patients before and after initiating RA treatment (table 7-3 on following page) .  
These parameters included LV and RV volumes, ejection fraction and mass, LV 
deformation indices (S’, torsion and twist), myocardial native T1, myocardial extra 
cellular volume fraction and late Gadolinium enhancement (LGE).  Myocardial 
perfusion will findings will be presented elsewhere. 
Absolute LV mass (74 (IQR 63-96g) pre-treatment versus 79 (IQR 66-98g) post 
treatment, p =<0.001) as well as LV mass indexed to body surface area (42 (IQR 
38-48g/m2) pre-treatment versus 44 (IQR 38-50g/m2) , p = 0.002) increased 1 year 
after commencing treatment in all patients, but did not differ significantly between 
treatment groups.   
No other parameters showed any statistically significant differences either in all 
patients following treatment, or between the 2 treatment arms.  LV S’ (a measure of 
longitudinal LV systolic function) at 1 year was numerically higher in patients who 
received immediate Etanercept (1.15 (IQR 1.08-1.24) versus 1.12 (IQR 1.04-1.23) 
respectively, p= 0.18.  Native myocardial T1 (a measure of myocardial composition) 
was numerically lower in patients who received immediate Etanercept (1178 ± 69 
versus 1198 ± 55 respectively, p= 0.18). 
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Table 7-3 Secondary Outcomes Before and After Treatment 
 
 
*Mean ± SD or median (IQR) unless stated otherwise 
 
 
 
 
 
 
 
Parameter* All patients 
baseline 
(n=71) 
All patients 1 
year (n=71) 
p value 
(baseline 
vs. 1 year) 
Immediate 
Etanercept at 
1 year (n=35) 
Delayed 
Etanercept at 
1 year (n=36) 
p value 
(Immediate 
vs. delayed) 
LVEDV 148 ± 31 149 ± 31 0.46 149 ± 28 149 ± 34 0.96 
LVEDV 
(indexed to 
BSA) 
80 ± 12 80 ± 12 0.66 80 ± 12 81 ± 12 0.70 
LVEF (%) 60 (58-65) 61 (58-64) 0.47 61 (55-63) 62 (59-65) 0.13 
LV Mass 
(g) 
74 (63-96) 79 (66-98) 0.001 77 (69-96) 82 (62-104) 0.99 
LV Mass 
indexed to 
BSA 
42 (38-48) 44 (38-50) 0.002 43 (38-49) 44 (38-54) 0.67 
RVEF (%) 54 ± 5 55 ± 6 0.37 54 ± 6 55 ± 6 0.48 
S’ (s-1) 1.16 (1.06-
1.25) 
1.13 (1.07-
1.23) 
0.61 1.15 (1.08-
1.24) 
1.12 (1.04-
1.23) 
0.18 
Peak twist 
(degrees) 
15.4 ± 3.5 15.4 ± 3.8 0.85 15.5 ± 4.0 15.3 ± 3.7 0.80 
Peak 
torsion 
(degrees) 
13.7 ± 3.1 13.2 ± 3.2 0.26 13.4 ± 3.3 13.1 ± 3.2 0.67 
Native 
myocardial 
T1 (ms) 
1183 ± 42 1188 ± 62 0.46 1178 ± 69 1198 ± 55 0.18 
Myocardial 
ECV (%) 
27 ± 4 27 ± 3 0.06 26 ± 3 27 ± 3 0.74 
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7.3.3. Patterns of late gadolinium enhancement 
A total of 10/71 patients (14%) showed evidence of abnormal hyperenhancement 
on LGE imaging either at baseline, 1 year CMR or both (patterns of LGE are shown 
in figure 7-3).  All were non-infarct patterns.  The majority (8/10) affected the mid-
wall mid inferior RV insertion point and were either focal (7/8) or patchy (1/8).  The 
remaining patterns seen were linear, mid wall hyperenhancement of the mid 
antero/inferoseptum (1/10) and patchy midwall hyperenhancement of basal 
inferolateral segment (1/10). 
 
Figure 7-3 Patterns of LGE in RA 
 
Panel A shows the most common inferior RV insertion point pattern, panel B shows 
linear septal LGE and panel C shows patchy lateral midwall LGE 
 
 
 
 
7.4. Discussion 
This prospectively conducted single-centre randomised control trial is, to our 
knowledge, the first to assess the impact of modern DMARD therapy on CMR 
markers of subclinical CVD in patients with newly-diagnosed, treatment naïve RA 
and no prior history of CVD.  Unlike previous non-invasive imaging studies of RA 
patients which have been limited by their inclusion of heterogeneous patient 
populations with established RA and/or patients with known cardiovascular disease, 
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this study excluded patients with established RA, those previously treated with 
DMARDs as well as known cardiovascular disease. 
We have demonstrated that aortic distensibility, a measure of aortic stiffness and 
surrogate marker for increased risk of CVD, improves markedly after initiation of RA 
treatment in those treated with either first-line ETN-MTX or first line MTX-T2T ± 
ETN-MTX.  We have also shown a clear signal that ETN-MTX provides additional 
benefit over and above standard therapy with evidence of greater improvements in 
aortic stiffness which persist after adjustment for disease activity score. Of note, 
25% difference was observed between first-line standard therapy non-responders 
(that received delayed ETN) to responders and similarly between all receiving ETN 
(first-line and delayed) and first-line standard therapy responders. 
Lastly, we have demonstrated an increase in LV mass following treatment for RA in 
those treated with either first-line ETN-MTX or first line MTX-T2T ± ETN-MTX.  
Other markers of subclinical CVD including LV strain indices, ECV and native 
myocardial T1 relaxation time do not differ significantly after with treatment. 
 
7.4.1. Aortic stiffness in RA 
In recent years, greater understanding has been gained of the contribution of age-
related stiffening of larger arteries to the development of heart disease, CV events 
and microvascular disease of the major organs; collectively termed the ageing 
vascular continuum(223).  RA is thought to accelerate this process, initially through 
increased vascular tone and subsequently via development of atherosclerotic 
plaque(147).  
 A number of previous studies have demonstrated reduced aortic stiffness using a 
variety of non-invasive imaging techniques in patients with established RA.  Provan 
et al. showed in a cross-sectional study that RA patients in clinical remission had 
lower augmentation index values than patients with active RA(225).  More recently, 
Ikdahl et al. demonstrated that high augmentation index and aortic pulse wave 
velocity values were predictive of CV events in 138 patients over a 6-year follow-up 
period(248).  Our own results are the first to demonstrate improvements in aortic 
stiffness following treatment initiation in a treatment naïve RA cohort.  Importantly, 
treatment with ETN-MTX (whether as first or second line therapy) appears to 
provide additional benefit over standard therapy.   This was evidenced by 
comparison of all first-line ETN-MTX (group 1) and all first line MTX-T2T ± ETN-
MTX (group 2) which showed a numerical improvement in favour of first line ETN-
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MTX.  Comparison of first-line MTX-T2T non-responders who received ETN-MTX 
(group 2b) versus first line MTX-T2T responders (group 2a) who did not, showed a 
substantial (25%) improvement in aortic distensibility in favour of ETN-MTX.  Lastly, 
comparison of all patients receiving ETN-MTX at any stage (groups 1+2b) with first-
line MTX-T2T responders (group 2a) showed a similar 24% improvement in aortic 
distensibility in favour of ETN-MTX.  
7.4.2. LV mass and LGE in RA 
We have demonstrated in this study an apparent increase in LV mass and LV mass 
indexed to body surface area following RA treatment (irrespective of treatment 
arm).  Table 6-3 in the preceding chapter demonstrates that LV mass was reduced 
in at the time of diagnosis in patients with early RA, thus this increase actually 
reflects a shift towards normalisation of LV mass in response to RA treatment 
initiation.  As such, this normalisation of LV mass is likely to indicate a degree of 
recovery and positive LV remodelling in response to RA treatment rather than an 
indication of deleterious effects of RA treatment.   
Reduced LV mass when comparing RA patients to healthy controls has been 
reported in other studies assessing established RA (167, 171) although its cause is 
unclear.  Experimental animal models have shown LV dilatation and systolic 
impairment, coupled with LV wall thinning(249) and myocardial collagen deposition 
in response to elevated TNF-α(250) thus LV remodelling may be a direct effect of 
TNF-α.  A second plausible explanation could be that reduced LV myocardial mass 
relates to the phenomenon of ‘rheumatoid cachexia’ which is linked to a 
combination of inflammation and reduced physical activity in RA patients.   A high 
proportion of RA patients exhibit rheumatoid cachexia, which manifests as reduced 
skeletal muscle mass in combination with increased fat mass(251) and such 
individuals may have poorer CV outcomes.  It is possible that the reduction in 
muscle mass extends beyond skeletal muscle to involve the myocardium in patients 
with rheumatoid cachexia. 
Our finding of a sizeable proportion of RA patients (14%) with non-ischaemic 
abnormal LGE corresponds broadly to those of Ntusi et al. who assessed 39 
established RA patients using multi-parametric CMR and found focal, 
predominantly non-ischaemic LGE in 46% of RA patients.  The lower rates we have 
reported are likely related to the much shorter disease duration in our study 
population.  The cause of LGE in RA possibly reflects active or previous myocarditis 
which is a widely reported finding in RA(125). 
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7.4.3. Study Limitations 
It is important to acknowledge that our analyses of aortic distensibility across 
treatment group and subgroups are exploratory in nature, in line with the study 
design and the absence of comparable previous study data.  Therefore, although 
aortic distensibility values across these groups and subgroups have been assigned 
‘p values’ (that did not reach conventional statistical significance levels), we would 
highlight that p-values are in reality not suitable in an exploratory analysis of pilot 
study data such as these(252), thus we feel the appropriate interpretation is of a 
signal whereby ETN-MTX appears to confer a benefit over standard therapy.  We 
did not detect any significant differences in measures of LV systolic function (LVEF, 
LV S’, LV twist and LV torsion) following treatment in all patients and between 
treatment groups.  Similarly we did not detect any differences in myocardial T1 and 
ECV.  Possible reasons for this include our sample size and, secondly, that our 
study population involved patients with newly diagnosed RA.  Significant changes in 
these parameters may occur later in the course of the disease, a factor which 
should be addressed in part by the planned 2-year follow up scan which will be 
conducted and reported as part of the CADERA study protocol. 
 
7.5. Conclusion 
Aortic distensibility, a measure of aortic stiffness and surrogate marker of increased 
risk of CV disease is decreased in treatment naïve, newly diagnosed RA and 
improves markedly with initiation of RA therapy.  Treatment with Etanercept in 
combination with Methotrexate (whether first or second-line) appears to confer 
additional benefit in terms of improvement in aortic stiffness above standard 
therapy. 
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8. Discussion 
Cardiovascular disease remains a major cause of morbidity and mortality in the 21st 
century and improving its diagnosis in treatments constitutes a worldwide health 
priority.  As non-invasive cardiovascular imaging improves and evolves, this allows 
insights to be gained into mechanisms by which cardiovascular diseases occur and 
progress.  Furthermore, this offers the opportunity to detect disease before 
symptoms occur, potentially mitigating serious late complications of that disease.   
The overarching aim of this thesis was to explore and refine the utility of both 
existing and emerging cardiovascular magnetic resonance imaging techniques in 
the context of subclinical cardiovascular disease, with a particular emphasis on both 
prior myocardial infarction and rheumatoid arthritis.  Cardiovascular magnetic 
resonance imaging is ideally suited to this aspect of exploratory cardiovascular 
research on the basis of its lack of use of non-ionising radiation and inherently 
quantitative nature which vastly reduces subjectivity of assessment and allows 
reproducible comparison of studies across patient groups.   
Chapters 3 and 4 were CMR methods development chapters aiming to improve 
upon and refine existing techniques in CMR suitable in the assessment of 
subclinical CV disease in cardiomyopathy evaluation (chapter 3) and assessment of 
aortic stiffness (a potential biomarker of heightened cardiovascular risk) in chapter 
4.  
Chapters 5 and 6 aimed to apply quantitative CMR parameters to subclinical 
disease states (myocardial infarction and across a spectrum of time points in the 
disease course of rheumatoid arthritis respectively) and assess their usefulness in 
the detection of these disease states.  
Lastly, chapter 7 assessed the relative impact of two different rheumatoid arthritis 
treatment strategies on subclinical CMR markers of subclinical cardiovascular 
disease. 
8.1. Discussion, study limitations and future 
directions relating to chapter 3  
Chapter 3 “Methodology for the development of ‘synthetic’ extracellular volume 
fraction at 1.5T and 3.0T” aimed to assess whether a patient’s blood pool native T1 
value could be used to approximate blood haematocrit and thereby used to derive 
their ‘synthetic’ myocardial ECV value.  The potential benefit in doing so was to 
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remove the time, cost and inconvenience associated with obtaining a venous 
haematocrit value which has clear benefits in terms of workflow in both the research 
and clinical setting.  This was the first study to demonstrate a high correlation of 
synthetic and laboratory ECV at 3.0T and also validated the technique for the first 
time on a 1.5T Philips system.  This finding potentially broadens the applicability of 
the technique across vendors and field strengths and may be of particular benefit in 
the research arena in the generation of immediate ‘in-line’ ECV maps and, in the 
clinical setting, of reducing the expense and time associated with obtaining a 
haematocrit sample.  Furthermore, the study showed good correlation between 
1.5T laboratory and synthetic ECV values derived using our own equation and 
values derived using an equation from a previous study using a Siemens MOLLI 
pulse sequence(188).  The potential significance of this finding is that the equations 
generated in this study may be interchangeable across vendors- potentially 
meaning that they could be used by other centres without the need for them to 
derive their own linear regression equations using a derivation cohort on their own 
scanner, though some negative bias in ECV was demonstrated.   
There were some limitations in the study; primarily that the native blood bool T1 and 
venous haematocrit was only moderately correlated at both field strengths, with a 
suggestion that values at both low and high extreme values were more prone to 
inaccuracy than those closer to the mean. Nevertheless, this did not appear to 
affect overall laboratory and synthetic ECV correlation- likely in part due to the 
relatively low contribution of haematocrit component of the ECV equation and the 
relatively low proportion of patients with these extreme values in our study.  
Although this study showed a good correlation between alternative vendor synthetic 
ECV equations with laboratory derived ECV at 1.5T, this was not assessed at 3.0T 
and therefore it is not known whether the 3.0T synthetic ECV equation reported in 
this study could be used across an alternative vendor.  
We speculate that this technique will prove useful in the clinical and research arena 
as a valid alternative to obtaining laboratory venous haematocrit.  Key future 
directions for this technique include the assessment of influences such as pulse 
sequence (MOLLI, ShMOLLI, SASHA) on the accuracy of blood pool derived 
haematocrit estimation.  In order to refine the technique further, future studies in 
this area may also assess the influence of taking the native T1 blood pool 
measurement from alternative sites such as the left or right atrium, as well as the 
influence of heart rate, age and patient gender.  Lastly, the issue of whether these 
equations are suitable to be used in other centres on alternative vendor platforms, 
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or whether equations should be derived independently on each scanner should be 
explored. 
8.2. Discussion, study limitations and future 
directions relating to chapter 4  
Chapter 4 “Methodology for the development of aortic and circumferential  strain 
analysis using CMR feature tracking” was another methods development chapter 
aimed at improving upon existing CMR assessment of aortic stiffness in subclinical 
cardiovascular disease.  This sought to assess the feasibility and reproducibility of 
measuring radial and circumferential aortic strain (as an indicator of aortic stiffness) 
in healthy volunteers by applying CMR feature tracking as a post-processing 
software technique to short axis cine acquisitions of the ascending and descending 
aorta.  This study was the first to develop and assess this technique for measuring 
aortic stiffness using CMR and demonstrated that the technique was feasible- 
reliably producing systolic strain curves in healthy volunteers with an acceptably 
short analysis time.  Reproducibility (interstudy, interobserver and intraobserver 
reproducibility were assessed) of descending aortic strain (both radial and 
circumferential) was excellent and good for ascending aortic strain.  The 
significance of demonstrating this feasibility and reproducibility of aortic radial and 
circumferential strain was that other studies using speckle tracking 
echocardiography have shown a correlation of circumferential strain with 
atherosclerotic plaque in coronary arteries(228).  This presents the opportunity of 
exploring the potential of CMR aortic strain assessment to identify individuals at the 
highest risk of developing cardiovascular disease and consequently to target 
preventative therapies at such individuals.  
Limitations to this study were primarily its low number of subjects and narrow age 
range of subjects, such that the values generated could not be considered as a 
normal reference range for aortic strain values.  Other post-processing software for 
the measurement of CMR-feature tracking is available and the agreement between 
values across software vendors was not assessed in this study.  Furthermore, the 
strain values generated in this study were not validated against a reference 
standard technique such as speckle tracking echocardiography to demonstrate their 
validity.  
Future directions in this area of research should include the publication of reference 
values for aortic strain by CMR feature tracking, as well as validating the technique 
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against speckle tracking echocardiography.  Crucially, the ability of (if any) of aortic 
strain values to predict the incidence of cardiovascular events as well as their 
relative performance against conventional risk scores such as Framingham and Q-
Risk(125) should also be assessed, particularly as these are based upon incident 
cardiovascular events amongst general populations and are prone to inaccuracy in 
specific high risk patient populations such as rheumatoid arthritis where 
cardiovascular risk is frequently underestimated.  The validity of descending aortic 
strain by CMR feature tracking was partly tested in a later chapter, chapter 6 
“Assessment of Large Artery Involvement in Rheumatoid Arthritis Over Time: Prior 
to Diagnosis, at Diagnosis and in Established Disease” in terms of its ability to  
detect aortic stiffness in patients with Rheumatoid arthritis versus healthy controls 
as well as its ability to identify patients at the highest risk of cardiovascular events in 
a cohort of rheumatoid arthritis patients with proven carotid atherosclerotic plaque 
disease.  This further validation is vital if the technique is to become more widely 
adopted.  
8.3. Discussion, study limitations and future 
directions relating to chapter 5  
Chapter 5 “The utility of global longitudinal strain in the identification of prior 
myocardial infarction in patients with preserved left ventricular ejection fraction” 
aimed to assess the ability of longitudinal strain parameters (including global 
longitudinal strain as well as global longitudinal strain rate and early diastolic strain 
rate) to predict the presence of prior myocardial infarction in patients with and 
without CMR evidence of subendocardial late gadolinium enhancement consistent 
with myocardial infarction.  Prior myocardial infarction is prevalent in certain high 
risk patient populations(197) and associated with worse cardiovascular outcomes.  
Importantly, prior myocardial infarction may be subclinical i.e. present without a 
patient having presented with classical symptoms of myocardial infarction and 
therefore such patients may benefit from secondary prevention medications and/or 
further investigations or consideration for coronary revascularisation.  
Conventionally, prior myocardial infarction is suspected on left ventricular 
assessment by echocardiography (or CMR) when abnormalities in LV radial 
function are seen; either in terms of reduced LV ejection fraction, hypokinesis or 
akinesis in 2 or more contiguous LV segments (regional wall motion abnormality) or 
both.  However, reliance on such measures of LV radial function alone is insufficient 
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to exclude prior myocardial infarction as this may be present went these features 
are absent. 
In this study, we demonstrated that global longitudinal strain (as well as global 
longitudinal strain rate and early diastolic strain rate) are reduced in individuals with 
prior myocardial infarction as compared with healthy volunteers.  The overall ability 
of global longitudinal strain to correctly identify prior myocardial infarction was found 
to be modest (AUC 0.662, sensitivity 60%, specificity 72.5%).  The findings of this 
study highlight the limitations of radial strain assessment in the context of ischaemic 
heart disease and demonstrate an ability of global longitudinal strain to potentially 
‘flag up’ patients who may have prior myocardial infarction in spite of ‘preserved’ LV 
ejection fraction.  Although this study used CMR feature tracking to assess global 
longitudinal strain, this measurement can be made using other modalities such as 
echocardiography.  This is important as not all patients undergo CMR examination 
in the routine assessment of LV function and not all patients who undergo CMR 
examination are suitable for gadolinium contrast.   
There were a number of limitations to this study.  Firstly, GLS is by no means 
perfect in identifying prior MI in individuals with preserved LV ejection fraction; a 
normal GLS does not reliably exclude prior MI and a low GLS does not always 
imply prior MI.  Secondly, the contribution of cardiovascular risk factors such as 
hypertension, hypercholesterolaemia, smoking and diabetes was not assessed in 
this study, although multivariable analysis showed that none of these variable were 
independent predictors of GLS whereas prior MI was, suggesting the presence of 
prior MI rather than these risk factors was responsible for lower GLS in individuals 
with prior MI. 
Future directions in this area of research should seek to build on the findings of this 
study.  Although GLS alone exhibits a modest ability to predict the presence of prior 
MI, a combination of other quantitative non-invasive imaging parameters such as 
regional/segmental strain indices or native myocardial T1 values and/or clinical 
parameters such as presence of cardiovascular risk factors or ECG evidence of Q 
waves may help to refine and improve upon the detection of prior MI in high risk 
patient groups.  Further areas of research include the validation of GLS by feature 
tracking across post-processing software vendors as well as across non-invasive 
imaging vendors.  Lastly the validation of GLS in this cohort of patients with prior 
myocardial infarction in terms of long-term prognostication should be assessed and 
compared against more established quantitative parameters such as LV ejection 
fraction to determine with GLS offers improved prognostication.  
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8.4. Discussion, study limitations and future 
directions relating to chapter 6 
Chapter 6 “Assessment of Large Artery Involvement in Rheumatoid Arthritis Over 
Time: Prior to Diagnosis, at Diagnosis and in Established Disease” served 2 main 
purposes.  The first was to identify whether subclinical evidence of aortic stiffness 
(a surrogate marker of increased risk of future cardiovascular disease) assessed by 
CMR and including descending aortic strain developed in chapter 4 was present in 
different stages of the rheumatoid arthritis continuum; in newly diagnosed disease 
as well as patients without clinical evidence but at high risk of developing 
rheumatoid arthritis.  The second purpose was to assess whether CMR measures 
of aortic stiffness (again including the descending aortic strain method developed in 
chapter 4) was able to identify the presence of atherosclerotic plaque disease 
detected by CMR in a cohort of patients with well-established rheumatoid arthritis.  
Rheumatoid arthritis patients are at high risk of developing CV disease and are 
three times more likely to have had either an acute MI or unrecognised MI in the 
two years preceding formal diagnosis than age and sex matched individuals without 
RA(121).  Diagnosis of RA can only made once a patient develops symptoms and 
presents for assessment by a healthcare professional.  Perhaps unsurprisingly 
then, a subclinical autoimmune phase is described lasting months or in some cases 
years, where a patient is largely asymptomatic but has autoimmune abnormalities 
in the form of positive anti-cyclic-citrullinated peptide (ACPA), a highly specific 
serological marker for RA(226).  Having developed and assessed the reproducibility 
and feasibility of CMR feature tracking assessment of descending aortic radial and 
circumferential strain in chapter 4,  it was validated in this chapter in terms of its 
ability to detect subclinical aortic stiffness in rheumatoid arthritis and individuals at 
risk of rheumatoid arthritis versus healthy controls and directly compared with aortic 
distensibility, a more established method of assessing aortic stiffness using CMR.  
Carotid artery circumferential strain has been shown to correlate with coronary 
artery atherosclerotic plaque, thus we hypothesised that circumferential descending 
aortic strain in particular may demonstrate an ability to correctly identify CMR 
carotid plaque (a potential marker of high risk for future CV events) in established 
RA patients. 
Our finding of increased arterial stiffness in individuals at risk of developing RA 
compared with controls, similar in magnitude to that seen in newly diagnosed, 
treatment naïve RA is, to the best of our knowledge, the first time this has been 
reported.  This may be the first indication that subclinical arterial stiffening occurs 
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(and is detectable using non-invasive imaging) much earlier than has previously 
been demonstrated and potentially shifts research and clinical priority further 
towards an emphasis on much earlier diagnosis and treatment of RA with the 
intention of reducing cardiovascular events later in the disease course.  In this 
study, we also demonstrated a weak association between reduced aortic strain 
values by CMR and the presence of CMR detected atherosclerotic carotid plaque in 
patients with established RA.   
The study had a number of limitations.  The first of these was that the sample size 
of individuals at risk of RA (n=18) was low.  As such, the study should really be 
considered as a pilot study suggesting evidence of increased aortic stiffness prior to 
a clinical diagnosis of rheumatoid arthritis, but not definitively proving this is the 
case.  Additionally, although the ability of descending aortic circumferential strains 
to correctly predict the presence of carotid atherosclerotic plaque was better than 
that of aortic distensibility (AUC 0.604  vs. 0.530 respectively) this predictive 
accuracy was weak and not statistically significant.  Although ideally atherosclerotic 
plaque imaging and strain values would also have been assessed in the same large 
artery (carotid or descending aorta), cine imaging of the carotid artery was (or 
T1/T2/PD acquisitions of the descending aorta) were not available in this study.  
Nevertheless, the findings of the study suggest that aortic strain (as well as aortic 
distensibility) by CMR feature tracking is limited in its ability to correctly identify 
carotid artery atherosclerotic plaque (and possibly, therefore, patients at the very 
highest risk of cardiovascular events). 
Future research in this area should investigate larger numbers of ACPA positive 
patients with musculoskeletal symptoms at high risk of developing RA to confirm 
the findings of this small scale study with stratification of patients according to their 
predicted risk of RA to identify whether aortic stiffness increases incrementally with 
RA risk or whether aortic stiffness is directly mediated by ACPA positive 
autoimmune status.  Using ACPA positive and ACPA negative controls with no 
musculoskeletal symptoms would further contribute to answering this research 
question.   
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8.5. Discussion, study limitations and future 
directions relating to chapter 7  
The final chapter “CMR Assessment of Newly Diagnosed Treatment Naïve RA 
Patients at Baseline and 1 Year After Randomisation to either Etanercept & 
Methotrexate or Standard Therapy” utilised a quantitative multiparametric CMR in 
patients with newly diagnosed, treatment naïve RA before and 1 year after 
randomisation to either standard therapy or early biological therapy.  The primary 
objective was to establish whether (any) RA DMARD strategy is associated with 
improvement in aortic distensibility over a 1 year period.  The secondary objectives 
were to explore whether the following factors affect AD change over 1 year: 
 DAS28 control (DAS28 defined clinical response/non-response) 
 Therapeutic intervention (TNFi/MTX and conventional DMARD including MTX) 
The key finding of this study were that aortic distensibility improves markedly after 
initiation of RA treatment in those treated with either first-line ETN-MTX or first line 
MTX-T2T ± ETN-MTX.  A clear signal was also shown that ETN-MTX provides 
additional benefit over and above standard therapy with evidence of greater 
improvements in aortic stiffness which persist after adjustment for disease activity 
score.  Notably, a 25% difference was observed between first-line standard therapy 
non-responders (that received delayed ETN) to responders and similarly between 
all receiving ETN (first-line and delayed) and first-line standard therapy responders. 
LV mass increased following treatment for RA in those treated with either first-line 
ETN-MTX or first line MTX-T2T ± ETN-MTX.  Other markers of subclinical CVD 
including LV strain indices, ECV and native myocardial T1 relaxation time did not 
differ significantly after with treatment.   
To the best of our knowledge this study was the first to assess effects of modern 
RA therapy on subclinical cardiovascular disease assessed by non-invasive 
imaging.  Although the no statistically significant benefit in terms of aortic stiffness 
was shown between the ETN-MTX or first line MTX-T2T ± ETN-MTX groups, sub-
analysis of treatment strategies suggested a clear benefit associated with patients 
receiving ETN-MTX at any stage.  Recently published registry data suggests a 
reduction in incidence of MI among RA patients receiving anti-TNF therapy(243) 
versus those receiving standard DMARD therapy.  The exact mode by which this 
reduction occurs, but this may link to the reduced aortic stiffness demonstrated in 
this study.   
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Limitations of this study were that a larger sample size may have led to a 
statistically significant difference between the two treatment arms and strengthened 
the conclusions drawn from the sub-analysis indicating a probable benefit in aortic 
stiffness reduction from Etanercept therapy.  
 Future directions in this area are twofold; firstly follow up of patients entered into 
CADERA is on-going and a later study will report 2 year CMR findings across the 
two treatment strategies.  This may further address the question as to the optimal 
RA treatment strategy from a cardiovascular standpoint and whether the likely 
benefit from Etanercept is sustained over the longer term.  Secondly, a long-term 
CADERA patient registry linked to long-term clinical outcomes will shed light onto 
the prognostic performance of the quantitative CMR parameters included in the 
protocol for the CADERA study, which may be also be of future benefit in 
assessment of subclinical cardiovascular diseases other than RA. 
8.6. Overall future directions  
The perfect non-invasive biomarker would be one which was acceptable to the 
patient, which poses no short or long-term risk to that patient, providing accurate 
and reproducible measurements linking precisely to disease activity in a dynamic 
fashion as well as linking accurately to long-term prognostication in terms of 
morbidity and mortality.  For more widespread adoption of such a non-invasive 
biomarker to occur, the same biomarker should be cost efficient with rapid 
acquisition and analysis time.  In the context of the conditions assessed in this 
thesis (prior myocardial infarction and rheumatoid arthritis), future studies should 
aim to address the following: 
Prior myocardial infarction: 
A key priority in this condition within non-invasive imaging is to improve the 
accuracy of diagnosis, ideally without the need for intravenous contrast agent.  
There may be a single as yet undiscovered (CMR) imaging parameter able to 
detect prior MI with 100% sensitivity and specificity, or a combination of non-
invasive imaging and clinical parameters may be able to achieve this.  
Future studies in this area may seek to use CMR LGE to identify prior MI in a high 
risk patient population (poorly controlled diabetes, established rheumatoid arthritis 
or elderly population) and identify whether use of CMR and treating patients 
identified as having prior MI with aggressive secondary prevention therapy 
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improves outcomes versus standard care i.e. use of clinical risk scoring tools e.g. 
Framingham or Q-Risk.   
Other possible studies would be to assess the long-term prognostic implications of 
GLS in patients with prior MI yet preserved LVEF. 
Rheumatoid arthritis 
One of the key findings of this thesis has been an indication that anti-CCP 
individuals at risk of RA appear to exhibit early subclinical evidence of CVD (in the 
form of increased vascular stiffness) similar in degree to that of patients with a new 
clinical diagnosis of RA. As already mentioned, a larger study assessing more of 
these patients as well as the inclusion of an asymptomatic anti-CCP positive 
individuals as a control group is needed.  Beyond this, a randomised control trial 
assessing the effect of closer follow up and earlier initiation of RA therapy in the 
highest risk individuals linked to long-term joint and CVD outcomes would be 
indicated.   
Other key studies in Rheumatoid arthritis include the assessment of the 
performance of the non-invasive CMR biomarkers used in this study (AD, LV mass, 
T1, ECV etc.) in terms of predicting long-term treatment response as well as 
prognostication of CVD and all-cause mortality.  Lastly, a randomised control trial is 
needed to assess if CVD outcomes are improved with non-invasive (CMR) 
biomarker (or alternative non-invasive imaging modality) guided primary CVD 
prevention therapy versus clinical risk score guided primary CVD prevention 
therapy. 
8.7. Recently published literature 
The following section discusses studies relevant to this thesis published after 
writing the background chapter. 
Relevant to the work detailed in chapter 3, Raucci Jr. et al. recently published a 
study of the use of synthetic ECV in the paediatric and young adult congenital heart 
disease population and found that correlation of synthetic ECV with lab ECV was 
better with the use of a locally derived linear regression equation as opposed to 
previously published equation on a 1.5T Siemens CMR scanner(253).  Additionally, 
they showed that using a cut-off value to define normal versus abnormal ECV (3 
standard deviations above the mean value from a normal reference population) that 
synthetic ECV ‘misclassified’ ECV as abnormal/normal compared with the 
laboratory ECV value.  They concluded that the strength of synthetic ECV was 
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therefore was primarily as a research tool (i.e. across populations) rather than in 
individual clinical patients.  Nevertheless, it could be argued that their cut-off value 
to define normal versus abnormal is somewhat arbitrary given that the primary 
strength of ECV in a clinical setting is to identify highly abnormal values in infiltrative 
cardiomyopathies such as amyloid or HCM and that a small error (perhaps up to 
5%) is not clinically relevant. 
In relation to GLS assessed by CMR-FT, a recent study(254) showed that GLS 
assessed this way in a large (n=470) cohort of patients with LVEF <50% due to 
ischaemic or non-ischaemic aetiology showed a strong, independent association 
with mortality.  Although these patients had reduced rather than preserved LVEF, 
this highlights that GLS by CMR-FT is a robust technique with strong potential as a 
non-invasive imaging biomarker.  
Finally, in the context of anti-citrullinated protein antibody, Hermans et al recently 
reported raised ACPA in 11% of 275 recent STEMI patients with no history or prior 
diagnosis of RA with an independent association with long-term CVD mortality rates 
in ACPA positive patients(255).  The authors postulated that ACPA positivity may 
be an independent CVD risk factor.  As detailed in this thesis, it was unclear in our 
own small cohort of individuals at risk of RA whether ACPA positivity in itself led to 
impaired AD or whether their intrinsic propensity to develop RA was the cause of 
this finding.  As such this highlights what a key area of future research this is.  
 
8.8. Conclusions 
Multiparametric CMR is ideally suited to the furthering our understanding of 
subclinical cardiovascular disease, providing insights into disease mechanisms, 
diagnosis of a disease, as well as its progression over time. In this thesis we have 
demonstrated the ability of synthetic ECV derived from native blood pool T1 to 
provide robust estimation of myocardial extracellular volume fraction, as well as 
reporting the development of a highly reproducible, novel aortic strain parameters 
which was validated in RA patients demonstrating its ability to identify vascular 
stiffness in RA patients versus controls.  We have shown a moderate ability of GLS 
to correctly identify prior myocardial infarction.  For the first time we have 
demonstrated evidence of subclinical vascular stiffness in individuals at high risk of 
developing RA.  Lastly we have shown that vascular stiffness exhibited at the time 
of diagnosis of RA reverses with treatment for the condition 1 year after diagnosis 
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with a suggestion that a greater reversal occurs with Etanercept as compared with 
standard therapy. 
 
  
 
.   
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Notes on statistical analysis for chapter 7 
Results for the primary outcome (aortic distensibility) in chapter 7 “assessment of 
Large Artery Involvement in Rheumatoid Arthritis Over Time: Prior to Diagnosis, at 
Diagnosis and in Established Disease was conducted by intention to treat (ITT) 
analysis.  The overarching principle of ITT analysis is that all patients enrolled and 
randomised in a randomised control trial are analysed in the groups to which they 
were originally assigned.   
Where baseline CMR data, but no follow up 1 year CMR scan had been conducted, 
missing data were imputed by multiple imputation with assistance from a 
biostatistician (EH).  Multiple imputation makes some assumptions about missing 
data- namely that they are missing at random.  Importantly, it assumes that they 
were not missing due to the values themselves (for example because all the 
missing scans were systematically much higher or lower than the recorded follow 
up values). 
Treatment groups were as follows: 
 Group 1: First line ETN-MTX 
 Group 2: First-line MTX-T2T ± ETN-MTX 
Treatment subgroups were defined as follows: 
 Group 1a: First line ETN-MTX responders (24-wk DAS28-ESR ≥2.6) 
 Group 1b: First line ETN-MTX non-responders (24-wk DAS-ESR <2.6) 
 Group 2a: First line MTX-T2T responders remaining on MTX-T2T                                                        
(24-wk DAS28-ESR ≥2.6)       
 Group 2b: First line MTX-T2T non-responders escalating to ETN-MTX 
(24-wk DAS-ESR <2.6)  
 
A limitation of this approach is that there were some patients in the group 2 who 
were not strictly in DAS28-ESR defined remission at week 24 but were not 
escalated – this decision was based on the judgment of the treating clinician. 
For all patients with missing DAS28-ESR at week 24 due to reasons other than 
withdrawal for lack of efficacy were assumed to be responders in the initial analysis. 
Data were then re-imputed and reanalysed assuming they were non-responders. 
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Aortic distensibility values were natural log-transformed prior to analysis. Results in 
chapter 7 are therefore expressed as ratios between groups. 
The imputation model included the following variables at weeks 0, 12, 24, 36 and 
48: SJC44, RAI, CRP, ESR, physician VAS, patient general health VAS, patient 
pain VAS, patient disease activity VAS and early morning stiffness. Aortic 
distensibility at baseline and 1 year was included. The model also included age, 
gender, symptom duration, treatment and an indicator for whether the patient was a 
responder. 
Multiple imputation by chained equations was used to create 50 complete datasets, 
the results from which were combined according to Rubin’s rules.  
Adjusted analyses were performed via multiple regression with appropriate checks 
that data met the assumptions of the test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
